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Objective: The objective of this study was to compare the use of different 
comorbidity measures to predict future healthcare utilization and expenditures for 
diabetic patients. Methods: This was a retrospective study that included 8,704 diabetic 
patients enrolled continuously for three years in the Department of Defense TRICARE 
program. Administrative claims data were used to calculate six comorbidity measures: 
number of distinct medications, index-year healthcare expenditures, two versions of the 
Charlson Comorbidity Index (CCI), and two versions of the Chronic Disease Score 
(CDS). Linear regression models were used to estimate three health outcomes for one- 
and two-year post-index periods: healthcare expenditures (COST), number of 
hospitalizations (HOS), and number of emergency department visits (ED). Logistic 
 
 vi 
regression models were used to estimate binary outcomes (above or below the 90th 
percentile of COST; ≥ 1 HOS or none; ≥ 1 ED or none). Comparisons were based on 
adjusted R2, areas under the receiver-operator-curve (c statistics), and the Hosmer-
Lemeshow goodness-of-fit tests. Results: The study population had a mean age of 51.0 
years (SD = 10.5), and 46.3 percent were male. After adjusting for age and sex, the 
updated CCI was the best predictor of one-year and two-year HOS (adjusted R2 = 8.1%, 
9.3%), the number of distinct medications was superior in predicting one-year and two-
year ED (adjusted R2 = 9.9%, 12.4%), and the index-year healthcare expenditures 
explained the most variance in one-year and two-year COST (adjusted R2 = 35.6%, 
31.6%). In logistic regressions, the number of distinct medications was the best predictor 
of one-year and two-year risks of emergency department use (c = 0.653, 0.654), but the 
index-year healthcare expenditures performed the best in predicting one-year and two-
year risks of hospitalizations (c = 0.684, 0.676) and high-expenditure cases (c = 0.810, 
0.823). The updated CCI consistently outperformed the original CCI in predicting the 
outcomes of interest. Conclusions: In a diabetic population under age 65, the number of 
distinct medications and baseline healthcare expenditures appeared to have superior or 
similar powers compared to the CCI or CDS for the prediction of future healthcare 
utilization and expenditures. The updated CCI was a better predictor than the original 
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 Comorbidity adjustment measures are used frequently in health services and 
epidemiological research to compare patient health status or to control for confounding 
effects. The primary objective of this study is to compare the utility of two comorbidity 
adjustment measures, the Charlson Comorbidity Index and the Chronic Disease Score, in 
terms of their predictive power and accuracy for several health outcomes. These 
outcomes include one-year and two-year total healthcare expenditures, number of 
hospitalizations, and number of emergency department visits. Patients with diabetes 
enrolled in the Department of Defense TRICARE insurance program were used as the 
study population because diabetic patients tend to suffer from multiple chronic conditions 
in addition to diabetes. 
The following sections will discuss comorbidity, diabetes, the Department of 
Defense TRICARE program, study rationale, study objectives, and research hypotheses. 
1.2 COMORBIDITY 
 
Risk is a multifaceted construct that is as complex as it is abstract, yet ubiquitous 
in everyday life. In medical research, such risks could include potential side effects from 
prescription medications or serious adverse reactions to vaccines. Some risks are 
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measurable, such as age and sex, while others could not be evaluated as easily, such as 
the perception of control over one’s health status. Many attempts have been made to 
identify risk factors, variables associated with increased risks of certain diseases or 
conditions, which may be used to estimate the level of risk in an individual or a group of 
people. For example, elevated serum cholesterol level has long been recognized as a risk 
factor for coronary heart disease.1 
Iezzoni identified demographic characteristics, clinical factors (including 
comorbidity), socioeconomic factors, health-related behaviors, and patient attitudes as the 
most important risk factors in health services research.2 Among this large array of risk 
factors, comorbidity is one that has become increasingly popular in estimating a person’s 
health status, and much research has been conducted to measure comorbidity as well as to 
refine these measures. 
1.2.1 Definition of Comorbidity 
 
Comorbidities are “diseases unrelated in etiology or causality to the principal 
diagnosis.”3 Despite their textual similarities, comorbidity is different from 
“multimorbidity” and “complications” in their connotations. Conceptually, comorbidities 
are etiologically unrelated to the principal diagnosis and are established only after the 
principal diagnosis is established. On the other hand, multimorbidity refers to the 
                                                
1 William B. Kannel et al., "Factors of Risk in the Development of Coroniary Heart Disease - Six-Year 
Follow-up Experience: The Framingham Study," Annals of Internal Medicine 55, no. 1 (1961). 
2 Lisa I. Iezzoni, "Range of Risk Factors," in Risk Adjustment for Measuring Health Care Outcomes, ed. 




coexistence of multiple diseases in a patient, without defining an index disease or a 
primary diagnosis. 
The distinction between comorbidities and complications is not as conspicuous 
and unambiguous, as interpretations of the same clinical manifestation may vary under 
different circumstances. For example, blindness is regarded as a serious complication 
associated with poor glycemic control in diabetic patients, but it could also be viewed as 
a comorbidity instead of a complication if other diseases such as cataracts or glaucoma 
cause the blindness in a patient with diabetes. Nevertheless, in general, comorbidities 
should be distinguished from complications: while comorbidities are not etiologically 
related to the principal diagnosis, complications are usually unfavorable medical 
conditions resulting from the principal diagnosis. 
1.2.2 Reasons to Measure Comorbidity 
 
Measuring comorbidities is important for several reasons. In the clinical setting, 
the focus of care tends to center on a patient’s principal diagnosis, be it acute or chronic. 
Medications, diagnostic tests, and functional assessments are usually planned based on 
the symptoms presented by the patient and the diagnosis thus made. Yet, oftentimes 
healthcare providers encounter patients who have more than one clinical condition that 
deserves medication attention, and comorbidities may influence how a clinical decision is 
made or how a treatment plan is devised. For example, while calcium channel blockers 
are recommended for hypertensive patients with comorbid diabetes, the same drug class 
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is not recommended for patients with both hypertension and chronic kidney disease.4 
Whether and when a drug therapy should be initiated may depend on a patient’s 
comorbid conditions: hypertensive patients who have a diagnosis of heart failure should 
start drug therapy earlier than those who do not.5 Treatment goals may also vary due to 
differences in patients’ comorbidities.6 
The second reason to measure comorbidities is that they could serve as predictors 
of health outcomes, such as hospitalizations or emergency department visits. Intuitively, 
patients who have more comorbidities should be sicker than those with fewer or no 
comorbidities. Indeed, the number of comorbid conditions is correlated with the volume 
of health services utilization: patients who have more comorbidities tend to seek more 
services from primary care physicians and specialists and are more likely to be admitted 
into hospitals.7 Comorbidity is important in determining healthcare costs of patients.8 
Studies have shown that classification of patients is possible based on their healthcare 
costs and comorbidities.9,10 Identifying the subgroup of patients who utilize more 
                                                
4 Aram V. Chobanian et al., "The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report," Journal of the American 
Medical Association 289, no. 19 (2003). 
5 Ibid. 
6 David M. Nathan et al., "Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus 
Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes 
Association and the European Association for the Study of Diabetes," Diabetes Care 32, no. 1 (2009). 
7 Jeroen Struijs et al., "Comorbidity in Patients with Diabetes Mellitus: Impact on Medical Health Care 
Utilization," BMC Health Services Research 6, no. 1 (2006). 
8 Michael Shwartz et al., "The Importance of Comorbidities in Explaining Differences in Patient Costs," 
Medical Care 34, no. 8 (1996). 
9 Mary E. Charlson et al., "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic 
Disease in Primary Care Patients," Journal of Clinical Epidemiology 61, no. 12 (2008). 
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healthcare resources could be beneficial in that 1) early identification of these patients 
may bring about more timely care for them, and 2) that healthcare resources may be 
allocated more efficiently. 
Another reason to measure comorbidities has to do with its usefulness in 
controlling for confounding effects, especially in retrospective and observational studies. 
Unlike randomized controlled trials, in which subjects are usually screened by stringent 
inclusion and exclusion criteria, observational studies are based on “real-world” data 
from patients with diverse backgrounds and with different levels of health status. 
However, the need still exists for researchers to ascertain the baseline health status of 
subjects before any meaningful analyses can be conducted. Theoretically, the 
confounding effects resulting from the differences in patient characteristics can be 
minimized thorough randomization, but this approach may not always be feasible. In 
retrospective studies, random allocation of patients to treatment and control groups is 
rarely possible. The study objective may be to examine effectiveness in a “real-world” 
setting but not efficacy in a controlled setting. In addition, researchers may not have the 
luxury of excluding patients who are too sick because the sample size might become too 
small or the generalizability could be compromised. Hence, an alternate approach is to 
include comorbidities as a covariate and other risk factors in statistical models when 
“real-world” data are analyzed. Once the assumption of homogeneity across groups is 
satisfied, researchers can be more confident in exploring the true relationships between 
                                                
10 Shwartz et al., "The Importance of Comorbidities in Explaining Differences in Patient Costs." 
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the independent and dependent variables and making reasonable and meaningful 
comparisons and inferences. 
1.2.3 Comorbidity Adjustment Measures 
 
Like other risk factors, comorbidity assessment can be useful when it is properly 
identified and quantified. However, measuring comorbidities could be challenging 
because comorbid conditions may not be determined as easily as other risk factors such 
as age and sex. For instance, comorbidities may not be documented completely in an 
emergency department setting because time is limited and the focus of care is to alleviate 
an immediate ailment as rapidly as possible. Acute comorbidities are less likely to be 
recognized than chronic comorbidities because they may have resolved before or between 
clinic visits. Nevertheless, given the aforementioned reasons to measure comorbidity, 
researchers have attempted to develop methods to quantify comorbidities systematically. 
These measures are commonly referred to as comorbidity index, comorbidity score, 
severity measure, severity score, or risk adjustment tool, among others. Given the lack of 
consistent terminology, the following discussion will refer to these instruments as 
comorbidity adjustment measures.  
 The interest in developing comorbidity adjustment measures has grown over the 
past few decades, as these measures can be applied in several possible scenarios: 
comparison of comorbidity and general health status across patient groups; matching of 
subjects in case-control studies; setting reimbursement rates for hospitals or clinics; and 
evaluation of patient characteristics of respondents and non-respondents in survey 
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research. Compared to subjective clinical judgment of patient health status, the use of 
comorbidity adjustment measures is advantageous in that the chance of bias is 
minimized, since the evaluation of patients’ comorbidities is based on systematic reviews 
with predefined methodology. 
Further, because most of these measures produce a single composite numerical 
score, statistical efficiency is enhanced when these measures are applied in studies 
employing statistical models. This characteristic makes comorbidity adjustment measures 
particularly attractive when the study sample sizes are relatively small or when multiple 
hypotheses need to be tested. A single summary score enables researchers to adjust for 
patient comorbidity with only one variable, which in turn simplifies the process of model 
building as the number of covariates decreases significantly. Granted, information may 
be lost when a single numerical score is used to reflect such a complex construct, but on 
the other hand, trying to code every comorbid condition as a separate variable in 
statistical models may result in model over-fitting. Therefore, comorbidity adjustment 
measures may be preferable in research utilizing large databases, where analyses can be 
conducted on a considerable amount of information within a relatively short time period 
and at a minimal cost. 
One convenient way to quantify comorbidity is through a simple count of the 
number of comorbid conditions. However, this method fails to account for the varying 
degrees of severity inherent in different disease states. In order to account for the severity 
of diseases, Kaplan and Feinstein created one of the earliest comorbidity adjustment 
measures, which classifies comorbidities in diabetic patients through a scoring system 
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based on clinical consensual judgment.11 Over the years, myriad similar measures have 
been developed to assess comorbidities in patients with different diseases and in different 
settings. 
 Generally, comorbidity adjustment measures can be categorized based on the type 
of data used to derive the measures and the designated purposes of the measures. 
Comorbidity adjustment measures are usually based on two types of data: clinical 
diagnoses, which can be ascertained using the International Classification of Diseases 
(ICD) codes, or medication utilization, which can be identified using the American 
Hospital Formulary Service (AHFS) classification codes. The availability of diagnosis- 
and medication-based measures means that researchers may opt for either type of 
measure depending on what type of data are available. Depending on the purpose of a 
measure, it can also be classified as a general-purpose or a disease-specific measure. 
General-purpose comorbidity adjustment measures presumably may be used for any 
disease state and in any patient population, even though the development of these 
measures is invariably based on a pilot patient population of a certain disease. In contrast, 
disease-specific measures are designed to be used in patients with a particular disease. 
Arguably, disease-specific measures could better reflect comorbidities in a subgroup of 
patients than general-purpose measures because the distribution of comorbidities is likely 
to vary across patient populations with different disease states. 
                                                
11 Moreson H. Kaplan and Alvan R. Feinstein, "The Importance of Classifying Initial Co-Morbidity in 
Evaluating the Outcome of Diabetes Mellitus," Journal of Chronic Diseases 27 (1974). 
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 Although many proprietary and non-proprietary comorbidity adjustment measures 
have been developed and made available to researchers, the following discussion will 
focus on two general-purpose comorbidity adjustment measures that have been used 
extensively. One is the Charlson Comorbidity Index (CCI), a measure that is based on 
clinical diagnoses; the other is the Chronic Disease Score (CDS), which produces a 
summary comorbidity score based on medication use from pharmacy data. 
1.2.3.1 Charlson Comorbidity Index 
 
The CCI was developed empirically by Charlson and her colleagues, who 
examined the medical records of a cohort of patients admitted in a New York hospital to 
derive a weighted comorbidity index. Charlson et al. selected comorbid conditions that 
were presumably predictive of one-year mortality in the test group and subsequently 
validated the index in another group of patients with breast cancer.12 Based on the 
adjusted relative risks from the regression model, 19 comorbid conditions were assigned 
weights of one, two, three, or six.13 A composite score is produced for each patient by 
summing up the scores corresponding to the comorbid conditions the patient has. A lower 
CCI score is associated with a lower mortality rate in the following year. Conversely, a 
higher CCI score is predictive of a higher one-year mortality rate after the index year. 
Although the CCI reasonably predicts one-year mortality with a simple composite 
score, researchers need to review medical records and identify all relevant diagnoses of 
                                                
12 Mary E. Charlson et al., "A New Method of Classifying Prognostic Comorbidity in Longitudinal 




comorbidities in order to calculate the index score. However, researchers may not always 
have access to medical records, and reviewing medical records could also be a time-
consuming and tedious process. The advent of large administrative databases provides 
researchers with rich data sources from diverse settings that also require appropriate 
comorbidity adjustment. Therefore, several adaptations of the original CCI have been 
developed to facilitate its application in large database research; some notable versions 
include the Deyo, Dartmouth-Manitoba, and D’Hoore adaptations.14,15,16 
Deyo et al. adapted the original CCI for use with ICD-9-CM diagnosis and 
procedure codes in a group of Medicare patients who underwent lumbar spine surgery.17 
The Deyo adaptation used weights from the CCI to obtain two index scores for each 
patient, one based on the ICD-9-CM codes assigned when the patient was admitted to a 
hospital and one based on the codes assigned during the previous year prior to the 
admission. Both index scores, after division into four categories (i.e., 0, 1, 2, ≥3), were 
found to be significantly associated with in-hospital complications, short-term mortality, 
blood transfusion, discharge to nursing home, hospital length of stay, and total hospital 
                                                
14 Richard A. Deyo, Daniel C. Cherkin, and Marcia A. Ciol, "Adapting a Clinical Comorbidity Index for 
Use with ICD-9-CM Administrative Databases," Journal of Clinical Epidemiology 45 (1992). 
15 Patrick S. Romano, Leslie L. Roos, and James G. Jollis, "Further Evidence Concerning the Use of a 
Clinical Comorbidity Index with ICD-9-CM Administrative Data," Journal of Clinical Epidemiology 46, 
no. 10 (1993). 
16 William D'Hoore, André Bouckaert, and Charles Tilquin, "Practical Considerations on the Use of the 
Charlson Comorbidity Index with Administrative Data Bases," Journal of Clinical Epidemiology 49, no. 12 
(1996). 




charges.18 Although the magnitudes of these associations were not reported, the authors 
observed that the associations were still significant after controlling for age, which 
suggested that the adapted CCI explained additional variances in these variables 
compared to a model merely based on age.19 
The Dartmouth-Manitoba adaptation of the CCI was developed by Romano et al., 
who also tried to translate the original CCI for use with administrative databases. 
Compared to the Deyo adaptation, Romano et al. assigned slightly different sets of ICD-
9-CM codes to the comorbid conditions listed in the CCI.20 Two large administrative 
databases were utilized to test the CCI’s predictive ability in mortality and complications 
in patients undergoing coronary artery bypass graft surgery and intervertebral disc 
excision. The Deyo and Dartmouth-Manitoba adaptations produced similar prevalence 
estimates of individual comorbidities, and the overall predictive power of the CCI was 
comparable; however, they found that the empirical weights derived from multivariate 
analyses may be significantly different from those assigned in the original CCI if the 
outcome of interest and study population are different.21 For example, in the original CCI 
weighting system, a score of one was assigned to congestive heart failure, but Romano et 
                                                
18 Ibid. 
19 Ibid. 
20 Romano, Roos, and Jollis, "Further Evidence Concerning the Use of a Clinical Comorbidity Index with 




al. postulated that the same comorbidity should be assigned a score of three in patients 
who just underwent coronary artery bypass graft surgery.22 
Ghali et al. examined how at the individual patient’s level, the Deyo and 
Dartmouth-Manitoba coding schemes agreed or disagreed with each other in producing 
index scores and also attempted to derive a new set of weights based on the ICD-9-CM 
codes using the original CCI.23 Patients who underwent coronary artery bypass graft 
surgery in two separate years were selected, and the outcome of interest was in-hospital 
mortality. Their findings suggested that the difference between the Deyo and Dartmouth-
Manitoba adaptations was minimal, as the scores agreed perfectly with each other in nine 
out of ten cases; they also argued that study-specific weights should be developed and 
used whenever possible because of improved model discrimination power.24 In a separate 
study, the Deyo and Dartmouth-Manitoba adaptations were found to agree with each 
other more than 80 percent of the time.25 
D’Hoore et al. also adapted the original CCI for use with administrative databases 
and used the ICD-9 codes without the two-digit clinical modification codes because 
sometimes only the first three ICD-9 codes are used or available.26 Namely, D’Hoore’s 
                                                
22 Ibid. 
23 William A. Ghali et al., "Searching for an Improved Clinical Comorbidity Index for Use with ICD-9-
CM Administrative Data," Journal of Clinical Epidemiology 49, no. 3 (1996). 
24 Ibid. 
25 Martin Nuttall, Jan van der Meulen, and Mark Emberton, "Charlson Scores Based on ICD-10 
Administrative Data Were Valid in Assessing Comorbidity in Patients Undergoing Urological Cancer 
Surgery," Journal of Clinical Epidemiology 59, no. 3 (2006). 
26 D'Hoore, Bouckaert, and Tilquin, "Practical Considerations on the Use of the Charlson Comorbidity 
Index with Administrative Data Bases." 
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coding scheme contained less information on diagnoses and no information on 
procedures. Data on 33,940 patients with ischemic heart disease were analyzed, and the 
adapted CCI was found to be significantly associated with inpatient one-year mortality in 
two consecutive years.27 D’Hoore et al.’s findings demonstrated that the predictive ability 
of the CCI remains reasonable without the clinical modification codes. Nevertheless, no 
studies had compared all three adaptations concurrently.  
The CCI has also been adapted for use with ICD-10 codes,28 but the most notable 
recent update was conducted by Charlson et al., who used Deyo’s coding scheme to 
predict healthcare costs in a primary care setting.29 They found that the adapted index 
was a better predictor of annual healthcare costs than a number of variables, including 
age, sex, and certain medications.30 The list of comorbidities was expanded to include 
depression, hypertension, use of warfarin (all with a weight of one), and skin ulcers or 
cellulitis (with a weight of two).31 The adaptation explained approximately one-fifth of 
the variance in annual healthcare costs and successfully identified patients who incurred 
high costs, the majority of whom were either Medicare or Medicaid beneficiaries.32 
                                                
27 Ibid. 
28 Nuttall, van der Meulen, and Emberton, "Charlson Scores Based on ICD-10 Administrative Data Were 
Valid in Assessing Comorbidity in Patients Undergoing Urological Cancer Surgery." 
29 Charlson et al., "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in 






The list of comorbid conditions and their associated weights and ICD-9 codes as 
assigned and adapted in different CCI adaptations are in Appendix A. Appendix B 
includes the four additional comorbid conditions and their associated ICD-9 code and 
generic code numbers. 
1.2.3.2 Chronic Disease Score 
 
Using automated pharmacy dispensing data from the Group Health Cooperative 
of Puget Sound, a Washington-based health maintenance organization, Von Korff et al. 
developed the Chronic Disease Score (CDS) that approximates an individual’s health 
status based on the type and number of prescription medications used by a patient.33 
Medications used to treat 17 different chronic conditions over a one-year period were 
identified, and weights were assigned by consensus judgment in order to calculate a total 
chronic disease score. The CDS was found to be a stable measure associated with patient 
health status and predictive of mortality and hospitalization rates after controlling for age 
and sex.  A patient with a higher CDS has poorer health status and is more likely to die or 
be hospitalized. Appendix C provides a detailed list of chronic conditions, medication 
classes, and weights used in the CDS. 
Clark et al. revised the original CDS by including more disease states (i.e., 
depression and other mental illnesses) and the list of medications for severity scoring; 
they also used empirically derived weights as opposed to the weights assigned based on 
                                                
33 Michael Von Korff, Edward H. Wagner, and Kathleen Saunders, "A Chronic Disease Score from 
Automated Pharmacy Data," Journal of Clinical Epidemiology 45, no. 2 (1992). 
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clinical judgment.34 Outpatient drug utilization data over a six-month period were 
examined to develop the revised CDS to predict total cost, outpatient care cost, and 
primary care visits.35 Compared to the original CDS, the revised CDS explained a higher 
proportion of variance in all three outcome variables both concurrently and prospectively; 
although a different method called the ambulatory diagnostic groups (ADGs) performed 
better than the revised CDS in explaining concurrent outpatient cost and primary care 
visits, the revised CDS explained more variance in total and outpatient costs than the 
ADGs in the prospective model.36 The revised CDS was also found to be associated with 
mortality and hospitalizations.37 Appendix D illustrates the list of chronic conditions, 
medication classes, and regression weights for prediction of total cost, outpatient cost, 
and primary care visits in the revised CDS. 
1.2.4 Assessing Comorbidity Adjustment Measures 
 
While comorbidity adjustment measures have been increasingly used in 
epidemiological and outcomes research, some have argued that the utility of these 
measures might be limited. Schneeweiss and Maclure contended that comorbidity 
adjustment measures should only be used in exploratory data analyses because a single 
composite score, as produced by most measures, could oversimplify a complex construct 
                                                
34 Daniel O. Clark et al., "A Chronic Disease Score with Empirically Derived Weights," Medical Care 33, 






like comorbidity and erroneously assume that the effects of comorbidities would be 
constant across different patient populations.38 Martins and Blais tested the CCI in a 
Brazilian population and found that different weights should be assigned to the original 
predictors in order to achieve optimal prediction of in-hospital mortality; they argued that 
some of the original predictors should be dropped and new predictors included.39 It has 
been proposed that a predictive statistical model similar to the CCI cannot explain more 
than 20% of the variance in patient healthcare expenditures.40 
 One major limitation of these measures is that their predictive performance is only 
as good as the data quality. Ideally, administrative databases should contain all relevant 
information on patient encounters, including demographic characteristics, health status, 
prior medical history, and medication use. However, rarely do researchers come across 
such a comprehensive database because the purpose of these databases is primarily for 
claims processing, and recording an excess amount of information is unnecessary and 
impractical. Coding errors are common, and under-coding of diagnoses is possible. One 
study compared the CCI derived from medical records with that from administrative 
databases and found that medical record data produced a CCI score that was more 
                                                
38 Sebastian Schneeweiss and Malcolm Maclure, "Use of Comorbidity Scores for Control of Confounding 
in Studies Using Administrative Databases," International Journal of Epidemiology 29 (2000). 
39 Mônica Martins and Régis Blais, "Evaluation of Comorbidity Indices for Inpatient Mortality Prediction 
Models," Journal of Clinical Epidemiology 59, no. 7 (2006). 
40 Rene C. J. A. van Vliet, "Predictability of Individual Helath Care Expenditures," The Journal of Risk 
and Insurance 59, no. 3 (1992). 
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powerful in predicting mortality and hospital length of stay, possibly because less 
information is recorded in the claims file of administrative databases.41  
Comorbidity adjustment measures have other limitations. First, their predictive 
power is sensitive to changes in study time frame: while the CCI is a reasonable predictor 
of one-year mortality, the Deyo and Dartmouth-Manitoba CCI adaptations predict 30-
day, 90-day, and 180-day mortalities poorly.42 Second, classification of comorbidity 
based on pharmacy data could be problematic because medication-based measures 
generally do not include non-prescription drugs, and some medications may have 
multiple indications or off-label uses. Third, any given comorbidity adjustment measure 
could only contain a limited list of comorbid conditions, and the range of these conditions 
could be more applicable in one patient population than another due to their associations 
with the principal diagnosis under investigation. The inclusion of additional comorbid 
conditions could improve a measure’s predictive power, albeit with ceiling effects.43 
As such, it is desirable to examine the utilities of comorbidity adjustment 
measures, especially when they are to be used to predict a different outcome, in a 
different population, or with a different time frame. Indeed, an increasing body of 
literature has been dedicated to the evaluation of available measures.44,45 Of particular 
                                                
41 Stephanie M. Kieszak et al., "A Comparison of the Charlson Comorbidity Index Derived from Medical 
Record Data and Administrative Billing Data," Journal of Clinical Epidemiology 52, no. 2 (1999). 
42 Mario A. Cleves, Nena Sanchez, and Mayumi Draheim, "Evaluation of Two Competing Methods for 
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Data," Journal of Clinical Epidemiology 50, no. 8 (1997). 
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44 Ronald Gijsen et al., "Causes and Consequences of Comorbidity: A Review," Journal of Clinical 
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interest, though, are empirical validation studies that compare two or more measures side 
by side in order to establish their relative performance. Such studies could provide 
valuable findings to researchers who need to choose a comorbidity adjustment measure 
that would align appropriately with their study objectives. Some studies have compared 
different types of diagnosis-based measures,46,47 while others compared diagnosis-based 
measures with medication-based measures.48,49 Despite the popularity of the CCI and 
CDS, only a few researchers have compared these two measures with each other.50,51 
Further, no evaluations have been made on these two measures’ predictive ability in 
patients with diabetes, even though diabetes is a prevalent chronic disease that has been 
studied extensively in outcomes and epidemiological research.52,53 
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1.3.1 Definition and Diagnostic Criteria for Diabetes 
 
Diabetes mellitus is a metabolic illness characterized by abnormally high blood 
glucose levels. Although some patients cannot be categorized easily into a specific type 
of diabetes, diabetes can be broadly classified into four clinical classifications based on 
its etiology: type 1 diabetes, caused by insufficient insulin production due to the loss of 
pancreatic beta cells; type 2 diabetes, caused by increased resistance or reduced 
sensitivity to insulin; gestational diabetes, any degree of glucose intolerance diagnosed 
during pregnancy; and other types of diabetes, induced by drugs or other disease states 
that impair pancreatic function.54 
A diagnosis of diabetes is made if a patient meets one of the diagnostic criteria in 
repeated tests: fasting plasma glucose level is equal to or higher than 126 mg/dl (7.0 
mmol/l); symptoms of hyperglycemia are presented with a random plasma glucose level 
equal to or higher than 200 mg/dl (11.1 mmol/l); or the two-hour plasma glucose level is 
equal to or higher than 200 mg/dl (11.1 mmol/l) during an oral glucose tolerance test.55 
Patients are diagnosed as pre-diabetic if their fasting plasma glucose levels fall between 
100 mg/dl (5.6 mmol/l) and 125 mg/dl (6.9 mmol/l) or if the two-hour plasma glucose 
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levels are between 140 mg/dl (7.8 mmol/l) and 199 mg/dl (11.0 mmol/l); pre-diabetes is 
associated with increased risks for diabetes and cardiovascular disease.56 
1.3.2 Treatment for Diabetes 
 
The choice of treatment for diabetes is principally dependent upon the type of 
diabetes presented by the patient, but other clinical (e.g., side effects of medications) and 
non-clinical factors (e.g., cost of treatment) are also taken into consideration in the 
decision process. Nevertheless, the overarching goals in treating different types of 
diabetes are to achieve and maintain appropriate blood glucose and hemoglobin A1C 
levels. 
The treatment for patients with type 1 diabetes includes insulin through injections 
or continuous subcutaneous infusion pumps, matching of after-meal insulin to food and 
physical activity, and insulin analogues.57 The management of type 2 diabetes employs a 
step-wise approach: the first line of therapy is a combination of lifestyle interventions and 
metformin. Insulin, sulfonylureas, pioglitazone, or exenatide may be employed as an 
additional therapy if glycemic goals are not achieved; a triple pharmacologic therapy 
consisting of metformin, pioglitazone, and a sulfonylurea may be considered but is not 
recommended; and all patients should be placed on metformin and intensive insulin 





therapy if poor glycemic control persists.58 The treatment for gestational diabetes 
includes lifestyle interventions and/or insulin injections.59 
1.3.3 Epidemiology and Economic Burden of Diabetes 
 
From 1980 to 2006, the number of Americans who were diagnosed with diabetes 
increased three-fold, and the prevalence rate more than doubled.60 While improvements 
in diagnostic techniques and longer life expectancy may be attributed to the increased 
prevalence of diabetes, the rising number of diabetic individuals in the United States may 
also be a result of sedentary lifestyles and widespread obesity. In 2007, an estimated 17.5 
million people, or 5.8 percent of the U.S. population, had been diagnosed with diabetes, 
reflecting a growth rate of approximately one million new cases per year since 2002; if 
those who were afflicted by the disease but undiagnosed were taken into account, then 
the total prevalence rate would increase to 8 percent.61 A recent estimate predicted that 
48.3 million people, or 12 percent of the U.S. population, will be diagnosed with diabetes 
by 2050.62 People who are older or of African American origin are more likely to suffer 
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from diabetes;63,64 males are slightly more likely than females to develop diabetes.65 
Diabetes is the sixth leading cause of death in the U.S.66 
Diabetes is a costly illness that burdens both patients and their families medically 
and economically. In 2007, the national total cost of diabetes was estimated to be $174 
billion, where $116 billion was attributed to direct medical costs and $58 billion was 
indirect costs related to reduced productivity, work loss, and premature mortality.67 For 
every 10 dollars spent on health care in the U.S., two dollars were spent by people with 
diabetes, of which one dollar was directly attributable to diabetes mainly because of the 
increased hospital admission rate and longer hospital length of stay.68 More significantly, 
diabetic patients incurred healthcare expenditures that were 2.3 times higher than those 
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1.3.4 Reasons to Measure Comorbidity in Persons with Diabetes 
 
Measuring comorbidities in diabetic patients is important for several reasons. 
First, diabetic patients often endure multiple comorbid conditions, and research on 
diabetes requires the careful consideration of comorbidities and their effects on patients. 
Ninety-six percent of Medicare beneficiaries with type 2 diabetes have at least one 
comorbidity, 46 percent suffer from five or more comorbidities, and about one in ten 
have more than ten comorbid conditions.70 In a Dutch population, almost half of the 
patients with diabetes had at least one comorbid condition.71 Further, diabetic patients are 
more likely to have depression,72 hypertension,73 coronary heart disease,74 and hip 
fractures75 than non-diabetic patients. Thus, research on diabetes is likely to be influenced 
by the confounding and mediating effects from comorbidities, and failure to control for 
such effects may bias study findings and interpretations. Although the importance of 
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accounting for comorbidity in the treatment of diabetes has long been recognized, its role 
in statistical analyses received attention much later.76 
Moreover, the coexistence of diabetes and comorbidities not only complicates the 
management of diabetes itself but also the treatment of the comorbid conditions. Patients 
who suffer from diabetes and other chronic diseases are less likely to receive treatments 
for other unrelated comorbid conditions.77 Under-diagnosis of comorbidities is common: 
about 45 percent of adult patients with both depression and diabetes have their depression 
undiagnosed and thus untreated.78 Even if depression is diagnosed, diabetic patients who 
have comorbid depression still have poorer quality of life79 and worse adherence to 
antidiabetic medications80 or glucose self-monitoring regimens.81 As such, timely 
identification and effective management of comorbidities in persons with diabetes seem 
to be a potential area of care where patient outcomes could be greatly improved.  
Studying diabetes and its comorbidities also has important implications in health 
services research. As mentioned earlier, diabetes is a costly disease, yet diabetic patients 
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seem to differ in their utilization of healthcare services depending on whether or not they 
have comorbidities. For example, diabetic patients with depression visit ambulatory care 
more often and have more prescriptions than those without depression; total health 
expenditures for patients with depression are 4.5 times higher compared to those without 
depression.82 In addition, as the severity of depression increases, the total of incurred 
healthcare costs also increase.83 Cardiovascular-related comorbidities, such as congestive 
heart failure and hypertension, are associated with increased odds of hospitalizations that 
may be prevented.84 Diabetic patients with non-cardiovascular type of comorbidities, 
such as musculoskeletal diseases and cancer, were found to have more hospital 
admissions and a longer hospital length of stay.85 One study using data from Medicare 
patients showed that about 7% of hospitalizations could be avoided in patients with type 
2 diabetes if both cardiovascular and non-cardiovascular related comorbidities were 
addressed clinically.86 
 In summary, because comorbidities are prevalent among diabetic patients, it is 
important to understand diabetes care within the context of comorbidities, and studies on 
diabetes and its comorbidities could bring potential benefits to various stakeholders: 
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clinicians could devise better treatment and management plans for diabetic patients with 
comorbid conditions; researchers could improve statistical analyses and data 
interpretation by appropriately adjusting for comorbidities; and policy makers could 
identify and address areas of diabetes care to promote more efficient use of health 
services. To enhance the understanding of comorbidities and their effects on healthcare 
utilization in diabetic patients, a large health insurer such as the Department of Defense 
TRICARE program would provide a rich data source for comparisons of different 
comorbidity adjustment measures. 
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1.4 DEPARTMENT OF DEFENSE TRICARE PROGRAM 
 
The TRICARE program is an integrated healthcare program within the Military 
Health System of the United States Department of Defense (DoD). It is managed by the 
TRICARE Management Activity under the Assistant Secretary of Defense for Health 
Affairs of the DoD and funded in large part by the Defense Health Program Operations 
and Maintenance appropriation.87 Historically, healthcare benefits for military retirees 
and family members were provided by the Civilian Health and Medical Program of the 
Uniformed Services (CHAMPUS), created through the passages of the Dependents 
Medical Care Act in 1956 and the Military Medical Benefits Amendments in 1966.88 In 
order to improve access to care and minimize costs, TRICARE was created in 1994 to 
replace CHAMPUS.89 It is a large network of healthcare resources drawn from the 
military forces and civilian health plans, providing comprehensive healthcare benefits to 
approximately 9.4 million beneficiaries worldwide, including active military personnel 
and their dependents, retirees and their dependents, and survivors.90  
Beneficiaries who are not Medicare-eligible may choose from one of the three 
TRICARE options, each with its own fee structure: TRICARE Prime, a health 
maintenance organization-type option; TRICARE Extra, a preferred provider option; and 
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TRICARE Standard, a fee-for-service option.91 In 2001, TRICARE for Life was initiated 
as a secondary payer to cover out-of-pocket expenses for those who are dually eligible for 
Medicare and TRICARE.92 In the United States, TRICARE is managed in three separate 
regions by three managed care contractors: Health Net (north), Humana (south), and 
TriWest (west).93 In fiscal year 2005, approximately 40 percent of the TRICARE 
beneficiaries were active duty personnel and dependents, while the other 60 percent were 
retirees and their dependents or TRICARE for Life retirees and dependents.94  
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1.5 STUDY RATIONALE 
 
As mentioned earlier, no studies have compared the utility of the Charlson 
Comorbidity Index and the Chronic Disease Score in predicting health-related outcomes 
for diabetic patients. One recent study found that the Charlson Comorbidity Index had 
similar utility in the prediction of healthcare expenditures among diabetic patients when 
compared with RxRisk-V, a medication-based adjustment measure.95 However, this study 
did not test the updated version of the Charlson Comorbidity Index nor include the 
Chronic Disease Score. In addition, the study was based on a Veteran population that was 
predominantly male. 
The current study compared the Charlson Comorbidity Index with the Chronic 
Disease Score using a nationally representative sample of TRICARE patients with 
diabetes. The study findings could help validate the updated version of the Charlson 
Comorbidity Index and also provide empirical evidence for choosing an appropriate 
comorbidity adjustment measure in health services and epidemiological research 
involving diabetic patients. 
                                                
95 Matthew L. Maciejewski, Chuan-Fen Liu, and Stephan D. Fihn, "Performance of Comorbidity, Risk 
Adjustment, and Functional Status Measures in Expenditure Prediction for Patients with Diabetes," 





The purpose of this study was to analyze the utility of the number of distinct 
medications, index-year total healthcare expenditures, Charlson Comorbidity Index 
(CCI), and the Chronic Disease Score (CDS) in predicting healthcare utilization and 
expenditures in patients with diabetes. Two adaptations of the CCI were used: the Deyo 
adaption and Charlson et al.’s 2008 adaptation, referred to as CCI-1 and CCI-2 
respectively hereafter. Both versions of the CDS were used, referred to as CDS-1 and 
CDS-2 hereafter. Data from the DoD TRICARE program were used to examine the 
measures’ predictive performance in one-year and two-year 1) total healthcare 
expenditures and high-expenditure individuals, 2) number and risk of hospitalizations, 
and 3) number and risk of emergency department visits.  
Three specific study objectives were to: 
1) Validate the CCI-2’s use in predicting one-year and two-year healthcare 
utilization and expenditures; 
2) Compare the use of six methods – index-year number of distinct medications, 
index-year total healthcare expenditures, CCI-1, CCI-2, CDS-1, and CDS-2 – in 
predicting future healthcare utilization and expenditures, after controlling for age and sex; 
and 
3) Evaluate whether combining a diagnosis-based measure (i.e., CCI) with a 
medication-based measure (i.e., CDS) produces significantly better predictive powers 





One-Year Total Healthcare Expenditures 
H1: Age and sex together significantly predict one-year total healthcare expenditures. 
Model1: One-year total healthcare expenditures = age + sex 
H2: The number of distinct medications in the index period is a significant predictor of 
one-year total healthcare expenditures, controlling for age and sex. 
Model2: One-year total healthcare expenditures = age + sex + number of distinct 
medications 
H3: The sum of total healthcare expenditures in the index period is a significant predictor 
of one-year total healthcare expenditures, controlling for age and sex. 
Model3: One-year total healthcare expenditures = age + sex + index-year total healthcare 
expenditures 
H4: CCI-1 is a significant predictor of one-year total healthcare expenditures, controlling 
for age and sex. 
Model4: One-year total healthcare expenditures = age + sex + CCI-1 
H5: CCI-2 is a significant predictor of one-year total healthcare expenditures, controlling 
for age and sex. 
Model5: One-year total healthcare expenditures = age + sex + CCI-2 
H6: CDS-1 is a significant predictor of one-year total healthcare expenditures, controlling 
for age and sex. 
Model6: One-year total healthcare expenditures = age + sex + CDS-1 
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H7: CDS-2 is a significant predictor of one-year total healthcare expenditures, controlling 
for age and sex. 
Model7: One-year total healthcare expenditures = age + sex + CDS-2 
H8: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict one-year total healthcare expenditures.  
Model8: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures 
H9: CCI-1 is a significant predictor of one-year total healthcare expenditures, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model9: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
H10: CCI-2 is a significant predictor of one-year total healthcare expenditures, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model10: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H11: CDS-1 is a significant predictor of one-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model11: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
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H12: CDS-2 is a significant predictor of one-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model12: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
H13: CDS-1 is a significant predictor of one-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model13: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
H14: CDS-2 is a significant predictor of one-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model14: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H15: CDS-1 is a significant predictor of one-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model15: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
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H16: CDS-2 is a significant predictor of one-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model16: One-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
One-Year High Healthcare Expenditures: greater than or equal to the 90th percentile of 
one-year total healthcare expenditures 
H17: Age and sex together significantly predict one-year high healthcare expenditures. 
Model17: One-year high total healthcare expenditures = age + sex 
H18: The number of distinct medications in the index period is a significant predictor of 
one-year high healthcare expenditures, controlling for age and sex. 
Model18: One-year high healthcare expenditures = age + sex + number of distinct 
medications 
H19: The sum of total healthcare expenditures in the index period is a significant predictor 
of one-year high healthcare expenditures, controlling for age and sex. 
Model19: One-year high healthcare expenditures = age + sex + index-year total healthcare 
expenditures 
H20: CCI-1 is a significant predictor of one-year high healthcare expenditures, controlling 
for age and sex. 
Model20: One-year high healthcare expenditures = age + sex + CCI-1 
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H21: CCI-2 is a significant predictor of one-year high healthcare expenditures, controlling 
for age and sex. 
Model21: One-year total high healthcare expenditures = age + sex + CCI-2 
H22: CDS-1 is a significant predictor of one-year high healthcare expenditures, 
controlling for age and sex. 
Model22: One-year high healthcare expenditures = age + sex + CDS-1 
H23: CDS-2 is a significant predictor of one-year high healthcare expenditures, 
controlling for age and sex. 
Model23: One-year high healthcare expenditures = age + sex + CDS-2 
H24: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict one-year high total healthcare expenditures.  
Model24: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures 
H25: CCI-1 is a significant predictor of one-year high healthcare expenditures, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model25: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
H26: CCI-2 is a significant predictor of one-year high healthcare expenditures, controlling 




Model26: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H27: CDS-1 is a significant predictor of one-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model27: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
H28: CDS-2 is a significant predictor of one-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model28: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
H29: CDS-1 is a significant predictor of one-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model29: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
H30: CDS-2 is a significant predictor of one-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model30: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
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H31: CDS-1 is a significant predictor of one-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model31: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
H32: CDS-2 is a significant predictor of one-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model32: One-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
Two-Year Total Healthcare Expenditures 
H33: Age and sex together significantly predict two-year total healthcare expenditures. 
Model33: Two-year total healthcare expenditures = age + sex 
H34: The number of distinct medications in the index period is a significant predictor of 
two-year total healthcare expenditures, controlling for age and sex. 
Model34: Two-year total healthcare expenditures = age + sex + number of distinct 
medications 
H35: The sum of total healthcare expenditures in the index period is a significant predictor 
of two-year total healthcare expenditures, controlling for age and sex. 




H36: CCI-1 is a significant predictor of two-year total healthcare expenditures, controlling 
for age and sex. 
Model36: Two-year total healthcare expenditures = age + sex + CCI-1 
H37: CCI-2 is a significant predictor of two-year total healthcare expenditures, controlling 
for age and sex. 
Model37: Two-year total healthcare expenditures = age + sex + CCI-2 
H38: CDS-1 is a significant predictor of two-year total healthcare expenditures, 
controlling for age and sex. 
Model38: Two-year total healthcare expenditures = age + sex + CDS-1 
H39: CDS-2 is a significant predictor of two-year total healthcare expenditures, 
controlling for age and sex. 
Model39: Two-year total healthcare expenditures = age + sex + CDS-2 
H40: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict two-year total healthcare expenditures.  
Model40: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures 
H41: CCI-1 is a significant predictor of two-year total healthcare expenditures, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model41: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
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H42: CCI-2 is a significant predictor of two-year total healthcare expenditures, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model42: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H43: CDS-1 is a significant predictor of two-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model43: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
H44: CDS-2 is a significant predictor of two-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model44: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
H45: CDS-1 is a significant predictor of two-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model45: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
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H46: CDS-2 is a significant predictor of two-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model46: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H47: CDS-1 is a significant predictor of two-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model47: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
H48: CDS-2 is a significant predictor of two-year total healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model48: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
Two-Year High Healthcare Expenditures: greater than or equal to the 90th percentile 
of two-year total healthcare expenditures 
H49: Age and sex together significantly predict two-year high healthcare expenditures. 
Model49: Two-year high total healthcare expenditures = age + sex 
H50: The number of distinct medications in the index period is a significant predictor of 
two-year high healthcare expenditures, controlling for age and sex. 
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Model50: Two-year high healthcare expenditures = age + sex + number of distinct 
medications 
H51: The sum of total healthcare expenditures in the index period is a significant predictor 
of two-year high healthcare expenditures, controlling for age and sex. 
Model51: Two-year high healthcare expenditures = age + sex + index-year total healthcare 
expenditures 
H52: CCI-1 is a significant predictor of two-year high healthcare expenditures, controlling 
for age and sex. 
Model52: Two-year high healthcare expenditures = age + sex + CCI-1 
H53: CCI-2 is a significant predictor of two-year high healthcare expenditures, controlling 
for age and sex. 
Model53: Two-year total high healthcare expenditures = age + sex + CCI-2 
H54: CDS-1 is a significant predictor of two-year high healthcare expenditures, 
controlling for age and sex. 
Model54: Two-year high healthcare expenditures = age + sex + CDS-1 
H55: CDS-2 is a significant predictor of two-year high healthcare expenditures, 
controlling for age and sex. 
Model55: Two-year high healthcare expenditures = age + sex + CDS-2 
H56: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict two-year high healthcare expenditures.  
Model56: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year high healthcare expenditures 
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H57: CCI-1 is a significant predictor of two-year high healthcare expenditures, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model57: Two-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
H58: CCI-2 is a significant predictor of two-year high healthcare expenditures, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model58: Two-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H59: CDS-1 is a significant predictor of two-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model59: Two-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
H60: CDS-2 is a significant predictor of two-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model60: Two-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
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H61: CDS-1 is a significant predictor of two-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model61: Two-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
H62: CDS-2 is a significant predictor of two-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model62: Two-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H63: CDS-1 is a significant predictor of two-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model63: Two-year high healthcare expenditures = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
H64: CDS-2 is a significant predictor of two-year high healthcare expenditures, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model64: Two-year high healthcare expenditures = age + sex + number of distinct 





One-Year Number of Hospitalizations 
H65: Age and sex together significantly predict one-year number of hospitalizations. 
Model65: One-year number of hospitalizations = age + sex 
H66: The number of distinct medications in the index period is a significant predictor of 
one-year number of hospitalizations, controlling for age and sex. 
Model66: One-year number of hospitalizations = age + sex + number of distinct 
medications 
H67: The sum of total healthcare expenditures in the index period is a significant predictor 
of one-year number of hospitalizations, controlling for age and sex. 
Model67: One-year number of hospitalizations = age + sex + index-year total healthcare 
expenditures 
H68: CCI-1 is a significant predictor of one-year number of hospitalizations, controlling 
for age and sex. 
Model68: One-year number of hospitalizations = age + sex + CCI-1 
H69: CCI-2 is a significant predictor of one-year number of hospitalizations, controlling 
for age and sex. 
Model69: One-year number of hospitalizations = age + sex + CCI-2 
H70: CDS-1 is a significant predictor of one-year number of hospitalizations, controlling 
for age and sex. 
Model70: One-year number of hospitalizations = age + sex + CDS-1 
H71: CDS-2 is a significant predictor of one-year number of hospitalizations, controlling 
for age and sex. 
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Model71: One-year number of hospitalizations = age + sex + CDS-2 
H72: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict one-year number of hospitalizations.  
Model72: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year number of hospitalizations 
H73: CCI-1 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model73: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
H74: CCI-2 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model74: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H75: CDS-1 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model75: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
 
46 
H76: CDS-2 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model76: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
H77: CDS-1 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model77: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
H78: CDS-2 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model78: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H79: CDS-1 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model79: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
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H80: CDS-2 is a significant predictor of one-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model80: One-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
One-Year Risk of Hospitalizations: Greater than or equal to one hospital admission in 
one year after the index period 
H81: Age and sex together significantly predict one-year risk of hospitalizations. 
Model81: One-year risk of hospitalizations = age + sex 
H82: The number of distinct medications in the index period is a significant predictor of 
one-year risk of hospitalizations, controlling for age and sex. 
Model82: One-year risk of hospitalizations = age + sex + number of distinct medications 
H83: The sum of total healthcare expenditures in the index period is a significant predictor 
of one-year risk of hospitalizations, controlling for age and sex. 
Model83: One-year risk of hospitalizations = age + sex + index-year total healthcare 
expenditures 
H84: CCI-1 is a significant predictor of one-year risk of hospitalizations, controlling for 
age and sex. 
Model84: One-year risk of hospitalizations = age + sex + CCI-1 
H85: CCI-2 is a significant predictor of one-year risk of hospitalizations, controlling for 
age and sex. 
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Model85: One-year total risk of hospitalizations = age + sex + CCI-2 
H86: CDS-1 is a significant predictor of one-year risk of hospitalizations, controlling for 
age and sex. 
Model86: One-year risk of hospitalizations = age + sex + CDS-1 
H87: CDS-2 is a significant predictor of one-year risk of hospitalizations, controlling for 
age and sex. 
Model87: One-year risk of hospitalizations = age + sex + CDS-2 
H88: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict one-year risk of hospitalizations.  
Model88: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures 
H89: CCI-1 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model89: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CCI-1 
H90: CCI-2 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model90: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CCI-2 
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H91: CDS-1 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model91: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CDS-1 
H92: CDS-2 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model92: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CDS-2 
H93: CDS-1 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model93: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CCI-1 + CDS-1 
H94: CDS-2 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model94: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CCI-1 + CDS-2 
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H95: CDS-1 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model95: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CCI-2 + CDS-1 
H96: CDS-2 is a significant predictor of one-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model96: One-year risk of hospitalizations = age + sex + number of distinct medications + 
index-year total healthcare expenditures + CCI-2 + CDS-2 
 
Two-Year Number of Hospitalizations 
H97: Age and sex together significantly predict two-year number of hospitalizations. 
Model97: Two-year number of hospitalizations = age + sex 
H98: The number of distinct medications in the index period is a significant predictor of 
two-year number of hospitalizations, controlling for age and sex. 
Model98: Two-year number of hospitalizations = age + sex + number of distinct 
medications 
H99: The sum of total healthcare expenditures in the index period is a significant predictor 
of two-year number of hospitalizations, controlling for age and sex. 




H100: CCI-1 is a significant predictor of two-year number of hospitalizations, controlling 
for age and sex. 
Model100: Two-year number of hospitalizations = age + sex + CCI-1 
H101: CCI-2 is a significant predictor of two-year number of hospitalizations, controlling 
for age and sex. 
Model101: Two-year number of hospitalizations = age + sex + CCI-2 
H102: CDS-1 is a significant predictor of two-year number of hospitalizations, controlling 
for age and sex. 
Model102: Two-year number of hospitalizations = age + sex + CDS-1 
H103: CDS-2 is a significant predictor of two-year number of hospitalizations, controlling 
for age and sex. 
Model103: Two-year number of hospitalizations = age + sex + CDS-2 
H104: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict two-year number of hospitalizations.  
Model104: Two-year total healthcare expenditures = age + sex + number of distinct 
medications + index-year number of hospitalizations 
H105: CCI-1 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model105: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
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H106: CCI-2 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model106: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H107: CDS-1 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model107: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
H108: CDS-2 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model108: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
H109: CDS-1 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model109: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
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H110: CDS-2 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model110: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H111: CDS-1 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model111: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
H112: CDS-2 is a significant predictor of two-year number of hospitalizations, controlling 
for age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model112: Two-year number of hospitalizations = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
Two-Year Risk of Hospitalizations: Greater than or equal to one hospital admission in 
two years after the index period 
H113: Age and sex together significantly predict two-year risk of hospitalizations. 
Model113: Two-year risk of hospitalizations = age + sex 
H114: The number of distinct medications in the index period is a significant predictor of 
two-year risk of hospitalizations, controlling for age and sex. 
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Model114: Two-year risk of hospitalizations = age + sex + number of distinct medications 
H115: The sum of total healthcare expenditures in the index period is a significant 
predictor of two-year risk of hospitalizations, controlling for age and sex. 
Model115: Two-year risk of hospitalizations = age + sex + index-year total healthcare 
expenditures 
H116: CCI-1 is a significant predictor of two-year risk of hospitalizations, controlling for 
age and sex. 
Model116: Two-year risk of hospitalizations = age + sex + CCI-1 
H117: CCI-2 is a significant predictor of two-year risk of hospitalizations, controlling for 
age and sex. 
Model117: Two-year total risk of hospitalizations = age + sex + CCI-2 
H118: CDS-1 is a significant predictor of two-year risk of hospitalizations, controlling for 
age and sex. 
Model118: Two-year risk of hospitalizations = age + sex + CDS-1 
H119: CDS-2 is a significant predictor of two-year risk of hospitalizations, controlling for 
age and sex. 
Model119: Two-year risk of hospitalizations = age + sex + CDS-2 
H120: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict two-year risk of hospitalizations.  
Model120: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures 
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H121: CCI-1 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model121: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures + CCI-1 
H122: CCI-2 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model122: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures + CCI-2 
H123: CDS-1 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model123: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures + CDS-1 
H124: CDS-2 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, and total healthcare expenditures in the 
index period. 
Model124: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures + CDS-2 
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H125: CDS-1 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model125: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures + CCI-1 + CDS-1 
H126: CDS-2 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-1. 
Model126: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures + CCI-1 + CDS-2 
H127: CDS-1 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model127: Two-year risk of hospitalizations = age + sex + number of distinct medications 
+ index-year total healthcare expenditures + CCI-2 + CDS-1 
H128: CDS-2 is a significant predictor of two-year risk of hospitalizations, controlling for 
age, sex, the number of distinct medications, total healthcare expenditures in the index 
period, and the CCI-2. 
Model128: Two-year risk of hospitalizations = age + sex + number of distinct medications 





One-Year Number of Emergency Department Visits 
H129: Age and sex together significantly predict one-year number of emergency 
department visits. 
Model129: One-year number of emergency department visits = age + sex 
H130: The number of distinct medications in the index period is a significant predictor of 
one-year number of emergency department visits, controlling for age and sex. 
Model130: One-year number of emergency department visits = age + sex + number of 
distinct medications 
H131: The sum of total healthcare expenditures in the index period is a significant 
predictor of one-year number of emergency department visits, controlling for age and 
sex. 
Model131: One-year number of emergency department visits = age + sex + index-year 
total healthcare expenditures 
H132: CCI-1 is a significant predictor of one-year number of emergency department visits, 
controlling for age and sex. 
Model132: One-year number of emergency department visits = age + sex + CCI-1 
H133: CCI-2 is a significant predictor of one-year number of emergency department visits, 
controlling for age and sex. 
Model133: One-year number of emergency department visits = age + sex + CCI-2 
H134: CDS-1 is a significant predictor of one-year number of emergency department 
visits, controlling for age and sex. 
Model134: One-year number of emergency department visits = age + sex + CDS-1 
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H135: CDS-2 is a significant predictor of one-year number of emergency department 
visits, controlling for age and sex. 
Model135: One-year number of emergency department visits = age + sex + CDS-2 
H136: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict one-year number of emergency department 
visits.  
Model136: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures 
H137: CCI-1 is a significant predictor of one-year number of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model137: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-1 
H138: CCI-2 is a significant predictor of one-year number of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model138: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-2 
H139: CDS-1 is a significant predictor of one-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
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Model139: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CDS-1 
H140: CDS-2 is a significant predictor of one-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model140: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CDS-2 
H141: CDS-1 is a significant predictor of one-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-1. 
Model141: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
H142: CDS-2 is a significant predictor of one-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-1. 
Model142: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H143: CDS-1 is a significant predictor of one-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-2. 
Model143: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
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H144: CDS-2 is a significant predictor of one-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-2. 
Model144: One-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
One-Year Risk of Emergency Department Visits: Greater than or equal to one 
emergency department visit in one year after the index period 
H145: Age and sex together significantly predict one-year risk of emergency department 
visits. 
Model145: One-year risk of emergency department visits = age + sex 
H146: The number of distinct medications in the index period is a significant predictor of 
one-year risk of emergency department visits, controlling for age and sex. 
Model146: One-year risk of emergency department visits = age + sex + number of distinct 
medications 
H147: The sum of total healthcare expenditures in the index period is a significant 
predictor of one-year risk of emergency department visits, controlling for age and sex. 
Model147: One-year risk of emergency department visits = age + sex + index-year total 
healthcare expenditures 
H148: CCI-1 is a significant predictor of one-year risk of emergency department visits, 
controlling for age and sex. 
Model148: One-year risk of emergency department visits = age + sex + CCI-1 
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H149: CCI-2 is a significant predictor of one-year risk of emergency department visits, 
controlling for age and sex. 
Model149: One-year total risk of emergency department visits = age + sex + CCI-2 
H150: CDS-1 is a significant predictor of one-year risk of emergency department visits, 
controlling for age and sex. 
Model150: One-year risk of emergency department visits = age + sex + CDS-1 
H151: CDS-2 is a significant predictor of one-year risk of emergency department visits, 
controlling for age and sex. 
Model151: One-year risk of emergency department visits = age + sex + CDS-2 
H152: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict one-year risk of emergency department visits.  
Model152: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures 
H153: CCI-1 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model153: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
H154: CCI-2 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
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Model154: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H155: CDS-1 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model155: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
H156: CDS-2 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model156: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
H157: CDS-1 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model157: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
H158: CDS-2 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model158: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
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H159: CDS-1 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model159: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
H160: CDS-2 is a significant predictor of one-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model160: One-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
Two-Year Number of Emergency Department Visits 
H161: Age and sex together significantly predict two-year number of emergency 
department visits. 
Model161: Two-year number of emergency department visits = age + sex 
H162: The number of distinct medications in the index period is a significant predictor of 
two-year number of emergency department visits, controlling for age and sex. 
Model162: Two-year number of emergency department visits = age + sex + number of 
distinct medications 
H163: The sum of total healthcare expenditures in the index period is a significant 




Model163: Two-year number of emergency department visits = age + sex + index-year 
total healthcare expenditures 
H164: CCI-1 is a significant predictor of two-year number of emergency department visits, 
controlling for age and sex. 
Model164: Two-year number of emergency department visits = age + sex + CCI-1 
H165: CCI-2 is a significant predictor of two-year number of emergency department visits, 
controlling for age and sex. 
Model165: Two-year number of emergency department visits = age + sex + CCI-2 
H166: CDS-1 is a significant predictor of two-year number of emergency department 
visits, controlling for age and sex. 
Model166: Two-year number of emergency department visits = age + sex + CDS-1 
H167: CDS-2 is a significant predictor of two-year number of emergency department 
visits, controlling for age and sex. 
Model167: Two-year number of emergency department visits = age + sex + CDS-2 
H168: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict two-year number of emergency department 
visits.  
Model168: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures 
H169: CCI-1 is a significant predictor of two-year number of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
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Model169: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-1 
H170: CCI-2 is a significant predictor of two-year number of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model170: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-2 
H171: CDS-1 is a significant predictor of two-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model171: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CDS-1 
H172: CDS-2 is a significant predictor of two-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model172: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CDS-2 
H173: CDS-1 is a significant predictor of two-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-1. 
Model173: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
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H174: CDS-2 is a significant predictor of two-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-1. 
Model174: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H175: CDS-1 is a significant predictor of two-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-2. 
Model175: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
H176: CDS-2 is a significant predictor of two-year number of emergency department 
visits, controlling for age, sex, the number of distinct medications, total healthcare 
expenditures in the index period, and the CCI-2. 
Model176: Two-year number of emergency department visits = age + sex + number of 
distinct medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
 
Two-Year Risk of Emergency Department Visits: Greater than or equal to one 
emergency department visit in two years after the index period 
H177: Age and sex together significantly predict two-year risk of emergency department 
visits. 
Model177: Two-year risk of emergency department visits = age + sex 
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H178: The number of distinct medications in the index period is a significant predictor of 
two-year risk of emergency department visits, controlling for age and sex. 
Model178: Two-year risk of emergency department visits = age + sex + number of distinct 
medications 
H179: The sum of total healthcare expenditures in the index period is a significant 
predictor of two-year risk of emergency department visits, controlling for age and sex. 
Model179: Two-year risk of emergency department visits = age + sex + index-year total 
healthcare expenditures 
H180: CCI-1 is a significant predictor of two-year risk of emergency department visits, 
controlling for age and sex. 
Model180: Two-year risk of emergency department visits = age + sex + CCI-1 
H181: CCI-2 is a significant predictor of two-year risk of emergency department visits, 
controlling for age and sex. 
Model181: Two-year total risk of emergency department visits = age + sex + CCI-2 
H182: CDS-1 is a significant predictor of two-year risk of emergency department visits, 
controlling for age and sex. 
Model182: Two-year risk of emergency department visits = age + sex + CDS-1 
H183: CDS-2 is a significant predictor of two-year risk of emergency department visits, 
controlling for age and sex. 
Model183: Two-year risk of emergency department visits = age + sex + CDS-2 
H184: Age, sex, the number of distinct medications, and index-year total healthcare 
expenditures together significantly predict two-year risk of emergency department visits.  
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Model184: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures 
H185: CCI-1 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model185: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 
H186: CCI-2 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model186: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 
H187: CDS-1 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model187: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-1 
H188: CDS-2 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, and total healthcare 
expenditures in the index period. 
Model188: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CDS-2 
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H189: CDS-1 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model189: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-1 
H190: CDS-2 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-1. 
Model190: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-1 + CDS-2 
H191: CDS-1 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model191: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-1 
H192: CDS-2 is a significant predictor of two-year risk of emergency department visits, 
controlling for age, sex, the number of distinct medications, total healthcare expenditures 
in the index period, and the CCI-2. 
Model192: Two-year risk of emergency department visits = age + sex + number of distinct 
medications + index-year total healthcare expenditures + CCI-2 + CDS-2 
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Chapter 2 Methodology 
 
This chapter discusses the methodology used for the study and consists of the 
following five sections: data source, study time frame, study sample, study design, and 
statistical analyses. 
2.2 DATA SOURCE 
 
This study used data from the Department of Defense TRICARE program’s 
Military Health System Data Repository/Military Health System Management Analysis 
and Reporting Tool (MDR/M2) and the Pharmacy Data Transaction Service Data 
Warehouse (PDTS). The MDR/M2 contains claims for medical services through: 1) 
military direct inpatient care (Standard Inpatient Data Record); 2) military direct 
outpatient care (Standard Ambulatory Data Record); 3) managed care inpatient services 
(TRICARE Encounter Data Institutionalized); and 4) managed care outpatient services 
(TRICARE Encounter Data Non-institutionalized). The PDTS supplies prescription data 
directly to the MDR/M2 and contains prescription claims for all three points of service 
(military pharmacies, mail-order pharmacies, community pharmacies). Table 2.1 
describes the data fields retrieved from MDR/M2 and PDTS. 
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Table 2.1: Descriptions of Data Fields from the TRICARE Military Health System 
(MHS) Data Repository/MHS Management Analysis and Reporting Tool and 
the Pharmacy Data Transaction Service (PDTS) Data Warehouse 
Data Field Description of Data Field 
From Cohort data file (containing patient demographic information) 
EDIPN Patient unique identifier 
DOB Date of birth 
Sex Sex 
ACV Alternate Care Value, indicating type of TRICARE enrollment of 
the beneficiary 
BENCATCOM Beneficiary Category Common, indicating beneficiary categories 
HSSCREG Beneficiary Health Services and Support Contract region, indicating 
the HSSC region of the beneficiary zip code 
From Standard Inpatient Data Record file 
EDIPN Patient unique identifier 
MTF Medical treatment facility 
PRN Patient record number 
FY Fiscal year based on disposition date 
DX1-DX20 First through twentieth ICD-9 diagnosis code 
PROC1-PROC20 First through twentieth ICD-9 procedure code 
ADMDATE Admission date 
DISPDATE Disposition date 
DISPTYPE Disposition status 
DMISDAYS Total bed days 
FULLCOST Full cost (the sum of medical, pharmacy, laboratory, and radiology 
costs plus payments by TRICARE, patients, and other insurers) 
FCANCLAB Ancillary laboratory portion of full cost 
FCANCRAD Ancillary radiology portion of full cost 
From TRICARE Encounter Data Institutionalized file 
EDIPN Patient unique identifier 
TEDNO TRICARE Encounter Data number 
INSTTYPE Type of institution 
ACUTE Acute care hospital indicator 
FY Fiscal year based on disposition date 
DX1-DX12 First through twelfth ICD-9 diagnosis code 
PROC1-PROC12 First through twelfth ICD-9 procedure code 
ADMTYPE Admission type 
ADMDATE Admission date 
BEGDATE Begin date of care 
ENDDATE End date of care 
DISPTYPE Disposition status 
TOTDAYS Total bed days 
 
72 
Table 2.1 (Continued) 
Data Field Description of Data Field 
PAID Total amount paid by TRICARE 
OHI Total amount paid by other health insurance 
PATCOST Total amount paid by patient 
From Standard Ambulatory Data Record file 
EDIPN Patient unique identifier 
APPTIDNO Appointment identification number 
DMISID Defense Medical Information System identifier for treatment 
FY Fiscal year based on disposition date 
ER Emergency department use identifier 
ENCDATE Encounter date 
DISPCODE Disposition code 
ICD1-ICD4 First through fourth ICD-9 diagnosis code 
CPT1-CPT10 First through tenth CPT (Current Procedure Terminology) code 
FCOST Full cost (the sum of medical, pharmacy, laboratory, and radiology 
costs plus payments by TRICARE, patients, and other insurers) 
FCLAB Full laboratory cost (laboratory portion of full cost) 
FCRAD Full radiology cost (radiology portion of full cost) 
FCRX Full pharmacy cost (pharmacy portion of full cost) 
From TRICARE Encounter Data Non-institutionalized file 
EDIPN Patient unique identifier 
TEDNO TRICARE Encounter Data number 
LINUM Line item number 
FY Fiscal year based on disposition date 
ERVIS Emergency department visit identifier 
DX1-DX8 First through eighth ICD-9 diagnosis code 
PAID Total amount paid by TRICARE 
OHI Total amount paid by other health insurance 
PATCOST Total amount paid by patient 
BEGDATE Begin date of care 
ENDDATE End date of care 
CPT Current Procedure Terminology code 
PLACE Place of service 
From Pharmacy Data Transaction Service Data Warehouse file 
EDIPN Patient unique identifier 
FY Fiscal year 
DATEDISP Date dispensed 
AUTHNUM Authorization number 
GCN Generic code number 
NDC National drug code 
AHFS American Hospital Formulary Service code 
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Table 2.1 (Continued) 
Data Field Description of Data Field 
RXNAME Product name 
DAYS Days supply 
ICOST Ingredient cost 
GAMT Sub gross amount 
COPAY Sub copay amount 
OHI Amount paid by other health insurance 
FILLOC Fill location 
From Laboratory/Ancillary data file 
EDIPN Patient unique identifier 
FY Fiscal year 
FULLCOST Full cost 
RECTYPE Record type 
SERVDATE Service date 
 
2.3 STUDY TIME FRAME 
 
This study used inpatient and outpatient claims data from October 1, 2005 to 
September 30, 2008. 
2.4 STUDY SAMPLE 
 
Eligible patients in the MDR/M2 database were identified using the following 
inclusion and exclusion criteria. 
Inclusion criteria: 
1. The patient had a diagnosis of diabetes (ICD-9-CM code 250.xx) using inpatient 
or outpatient services and at least one prescription claim for oral antidiabetic 




2. The patient was a non-active duty beneficiary continuously enrolled in the 
TRICARE Prime program for at least 10 of 12 months in each fiscal year from 
October 1, 2005 to September 30, 2008. 
Exclusion criteria: 
1. A female patient who had a prescription for prenatal vitamins anytime during the 
study period because she might have gestational diabetes. 
2. A patient who was born on or before September 30, 1943 (i.e., over 65 years of 
age at the end of the study period) because the patient might have received care 
through Medicare. 
3. A patient who received care outside the CONUS service area (i.e., 50 states, the 
District of Columbia, Puerto Rico, Guam and the U.S. Virgin Islands) at any time 
during the study period because records on healthcare expenditures may be 
incomplete. 
The final study sample consisted of approximately 10 percent of randomly 
selected sample of patients who met the inclusion and exclusion criteria. 
2.5 STUDY DESIGN 
 
This study was a retrospective cohort analysis. Patients were selected to enter the 
cohort based on the inclusion and exclusion criteria. Subjects were censored at the end of 
the study period. The fiscal year 2006 (October 1, 2005 to September 30, 2006) was set 
as the index year to identify age, sex, ambulatory encounters, and inpatient encounters, 
which were then used to calculate the index-period total healthcare expenditures, number 
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of distinct medications, the CCI scores, and the CDS scores. Healthcare utilization (i.e., 
emergency department visits, hospitalizations) and expenditures were identified for fiscal 
years 2007 and 2008. 
2.5.1 Comorbidity Assessment 
 
 Six different comorbidity adjustment measures were assessed: 
 The number of distinct medications in the index year was calculated as the sum of 
unique medications used. If two drugs had different doses but the same active ingredient, 
they were considered to be one unique medication. 
 Index-year total healthcare expenditures were calculated as the sum of amounts 
paid by TRICARE, other health insurance, and the patient for ambulatory visits, 
hospitalizations, emergency department visits, laboratory tests, radiological studies, and 
pharmaceuticals. 
Two adaptations of the CCI were used: the Deyo adaption (CCI-1) and Charlson 
et al.’s 2008 adaptation (CCI-2). Based on CCI-1, diagnoses were identified through 
ICD-9 codes and assigned weights of one, two, three, or six to obtain a summary score 
for each individual patient. Since the CCI-2 also bases its derivation on the CCI-1 coding 
scheme, the 19 original diagnoses were identified as described in CCI-1, while the three 
additional diagnoses (i.e., depression, hypertension, skin ulcers and cellulitis) were 
identified through their corresponding ICD-9 codes, and the use of warfarin was 
identified using the pharmacy prescription claims. All patients had a minimum CCI-1 or 
CCI-2 score of one because they had a diagnosis of diabetes. 
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Both Von Korff et al.’s CDS version (CDS-1) and Clark et al.’s CDS version 
(CDS-2) were used. For CDS-1, a summary integer score was produced based on the 
patient’s medication use. The CDS-2 includes more chronic conditions and medication 
classes than CDS-1 and presents three different sets of weights for prediction of total 
cost, outpatient cost, and primary care visits, respectively. For this study, the regression 
weights for total cost were used based on the developers’ recommendation.96 Medications 
that became available since 1992 were included in the calculation of scores if they were 
used to treat chronic conditions listed in the CDS-1 and CDS-2. Classification of drugs 
was based on the American Hospital Formulary Service (AHFS) codes, generic code 
numbers (GCNs), or drug names. 
2.5.2 Post-index Utilization Measures 
 
The cohort was followed up for two years to determine healthcare utilization and 
expenditures including: 1) total healthcare expenditures, 2) high-expenditure individuals, 
3) number of hospitalizations, 4) risk of hospitalizations, 5) number of emergency 
department visits, and 6) risk of emergency department visits. 
Post-index total healthcare expenditures were calculated as the sum of amounts 
paid by TRICARE, other health insurance, and the patient for ambulatory visits, 
hospitalizations, emergency department visits, laboratory tests, radiological studies, and 
pharmaceuticals. For total healthcare expenditures, a 90th percentile was ascertained to 
                                                
96 Clark et al., "A Chronic Disease Score with Empirically Derived Weights." 
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divide the patients into a high-expenditure group (≥ 90th percentile) and a low-
expenditure group (< 90th percentile).97 
The number of hospitalizations was calculated as the sum of inpatient admissions 
for any cause with total bed days equal to or more than one. The disposition date was 
used to determine in which fiscal year the hospitalization occurred. The risk of 
hospitalizations was defined as having one or more hospitalizations during the follow-up 
period. 
The number of emergency department visits was calculated as the sum of visits to 
the emergency department for any cause. The discharge date was used to determine in 
which fiscal year the emergency department visit occurred. The risk of emergency 
department visits was defined as having one or more emergency department visits during 
the follow-up period. 
2.6 STATISTICAL ANALYSES 
 
Descriptive statistics were calculated to examine the means, standard deviations, 
and distributions of demographics, healthcare utilization, and comorbidities of the 
patients. The predictive performance of the models was first examined by regressing the 
dependent variables on each set of predictors in multivariate linear regression models. An 
R2 statistic was produced from each regression model, representing the amount of 
variation in the dependent variable explained by the set of predictors. A higher R2 value 
                                                




indicates better overall prediction power, and vice versa. Thus, each model’s relative 
predictive performance may be ranked accordingly. 
Logistic regression analyses were conducted to examine model discrimination and 
calibration. For each logistic regression model, a c statistic was calculated, representing 
the area under curve of the receiver-operator characteristic (ROC). The ROC curves take 
into account correlations resulting from using the same sample of individuals,98 and are 
graphically presented as a plot of sensitivity and one minus specificity for all 
discrimination values of a predictor. Ideally, a predictor should be constructed in such a 
way that it could successfully identify true positive cases (i.e., sensitivity) while avoiding 
false positive cases (i.e., one minus specificity). A c statistic of 0.5 indicates no predictive 
ability because it is equivalent to random prediction; a c statistic of 1.0 indicates perfect 
prediction. The discriminating power of prediction models was tested by comparing the 
magnitudes of the c statistics. 
The Hosmer-Lemeshow goodness-of-fit chi-square test was conducted to examine 
the calibration of each logistic regression model. The test compares the observed and 
predicted number of cases of an outcome across a number of groups.99 In this study, the 
level of risk was categorized into deciles to test the calibration curves of the predictor 
models. If the distribution of predicted cases aligns well with the distribution of observed 
cases, then the model demonstrates good calibration, indicated by a low chi-square value. 
                                                
98 Elizabeth R. DeLong, David M. DeLong, and Daniel L. Clarke-Pearson, "Comparing the Areas under 
Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach," 
Biometrics 44, no. 3 (1988). 
99 Stanley Lemeshow and David W. Hosmer Jr., "A Review of Goodness of Fit Statistics for Use in the 
Development of Logistic Regression Models," American Journal of Epidemiology 115, no. 1 (1982). 
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Conversely, a higher chi-square value (i.e., a smaller p value) indicates poorer model fit 
and calibration. 
All statistical analyses were conducted using SAS®, and a p value of less than 
0.05 was considered statistically significant. 
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Chapter 3 Results 
 
This chapter presents the results from the analyses and consists of the following 
four sections: 1) descriptive statistics on the study sample, 2) modeling results on the 
prediction of total healthcare expenditures, 3) modeling results on the prediction of 
hospitalizations, and 4) modeling results on the prediction of emergency department 
visits. 
3.1 DEPARTMENT OF DEFENSE TRICARE STUDY SAMPLE 
 
The Department of Defense Pharmacoeconomic Center prescreened and randomly 
selected a sample of 9,000 patients meeting the study inclusion and exclusion criteria. 
Further examination of the claims records eliminated 295 patients who did not have a 
valid diabetes diagnosis in the index year and one patient whose sex was coded 
inaccurately. Therefore, the final study sample included 8,704 Department of Defense 
TRICARE beneficiaries with diabetes, including military personnel, retirees, and their 
dependents. All 8,704 patients had at least one inpatient or outpatient diagnosis of 
diabetes and at least one prescription claim for oral antidiabetic medication, insulin, or 
incretin mimetic between October 1, 2005 and September 30, 2006. All patients were 
under the age of 65, on non-active duty, and continuously enrolled in the TRICARE 
Prime program for at least 10 of 12 months in each fiscal year from October 1, 2005 to 
September 30, 2008. Patients were excluded if they received care outside the CONUS 
service area (i.e., 50 states, the District of Columbia, Puerto Rico, Guam and the U.S. 
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Virgin Islands) at any time during the study period. Patients were also excluded if they 
were female and had a prescription for prenatal vitamins during the study. 
Of the 8,704 patients, 4,674 (53.7%) were females and 4,030 (46.3%) were males. 
The mean (SD) age of the sample was 51.0 (10.5) years. The mean (SD) index-year total 
healthcare expenditures were $10,333 ($28,131), with a minimum of $119 and a 
maximum of $956,657. The mean (SD) index-year number of distinct medications was 
12.8 (7.3), with a minimum of one and a maximum of 65. Figure 3.1 shows the patient 
distribution by five-year age groups. 






The mean (SD) CCI-1 score in the study sample was 1.7 (1.2); the minimum was 
one and the maximum was 12. Figure 3.2 shows the distribution of the CCI-1 scores. 
Figure 3.2: Distribution of the Charlson Comorbidity Index – Deyo adaptation (CCI-1) 
Scores in the Study Sample (N=8,704) 
 
* The scores were derived using Deyo et al.’s adaptation: Deyo RA, Cherkin DC, and Ciol MA. "Adapting 
a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 





The mean (SD) CCI-2 score in the study sample was 2.7 (1.5); the minimum was 
one and the maximum was 15. Figure 3.3 shows the distribution of the CCI-2 scores. 
Figure 3.3: Distribution of the Charlson Comorbidity Index – 2008 version (CCI-2) 
Scores in the Study Sample (N=8,704) 
 
* The scores were derived using Charlson et al.’s 2008 version: Charlson ME, Charlson RE, Peterson JC, et 
al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care 





The mean (SD) CDS-1 score in the study sample was 7.4 (3.1); the minimum was 
two and the maximum was 23. Figure 3.4 shows the distribution of the CDS-1 scores. 
Figure 3.4 Distribution of the Chronic Disease Score – Von Korff Version (CDS-1) 
Scores in the Study Sample (N=8,704) 
 
* The scores were derived based on: Von Korff M, Wagner EH, and Saunders K. "A Chronic Disease 





The mean (SD) CDS-2 score in the study sample was 6,150 (3,012); the minimum 
was 3,046 and the maximum was 28,230. Figure 3.5 shows the distribution of the CDS-2 
scores. 
Figure 3.5: Distribution of the Chronic Disease Score – Clark Version (CDS-2) Scores in 
the Study Sample (N=8,704) 
* 
The scores were derived based on: Clark DO, von Korff M, Saunders K, et al. "A Chronic Disease Score 






Descriptive statistics on healthcare utilization and expenditures in the post-index 
one-year and two-year periods are presented in Table 3.1. 
Table 3.1: Total Healthcare Expenditures, Number of Hospitalizations, and Number of 
Emergency Department Visits for Diabetic Patients in One Year and Two 
Years Post-Index 






1 Year Post-Index $10,750 $26,661 $5,196 $21,711 $0 $959,359 
2 Years Post-Index $22,991 $50,522 $12,054 $45,323 $0 $1,721,847 
Number of 
Hospitalizations 
1 Year Post-Index 0.2 0.7 0 1 0 12 
2 Years Post-Index 0.4 1.2 0 1 0 19 
Number of Emergency 
Department Visits 
1 Year Post-Index 0.6 1.3 0 2 0 30 
2 Years Post-Index 1.2 2.2 0 3 0 50 
 
In the post-index one-year period, 871 patients had healthcare expenditures higher 
than $21,711 (i.e., 90th percentile), 1,177 patients had at least one hospital admission, and 
2,747 patients had at least one visit to the emergency department. In the post-index two-
year period, 871 patients had healthcare expenditures higher than $45,323 (90th 
percentile), 2,029 patients had at least one hospital admission, and 4,165 patients had at 





3.2 MODELING RESULTS: PREDICTION OF TOTAL HEALTHCARE EXPENDITURES 
3.2.1 One-year Total Healthcare Expenditures – Linear Regression Models: 
 
Controlling for age and sex, all six predictors produced significant increases of 
variance explained in one-year total healthcare expenditures: the number of distinct 
medications added an additional 7.2% of the variance (F = 681.0; df = 1, 8700; p < 
.0001); the index-year total healthcare expenditures added an additional 35.4% of the 
variance (F = 4778.9; df = 1, 8700; p < .0001); CCI-1 added an additional 11.0% of the 
variance (F = 1079.8; df = 1, 8700; p < .0001); CCI-2 added an additional 11.3% of the 
variance (F = 1110.9; df = 1, 8700; p < .0001); CDS-1 added an additional 3.6% of the 
variance (F = 329.4; df = 1, 8700; p < .0001); and CDS-2 added an additional 5.3% of the 
variance (F = 487.7; df = 1, 8700; p < .0001). 
 Controlling for age, sex, number of distinct medications, and index-year total 
healthcare expenditures, the four comorbidity adjustment measures contributed 
significant proportions of the variance in one-year total healthcare expenditures: 
including CCI-1 increased the variance explained by 0.8% (F = 112.1; df = 1, 8698; p < 
.0001); including CCI-2 increased the variance explained by 0.5% (F = 74.2; df = 1, 
8698; p < .0001); including CDS-1 increased the variance explained by 0.03% (F = 4.6; 
df = 1, 8698; p = .032); and including CDS-2 increased the variance explained by 0.03% 
(F = 5.6; df = 1, 8698; p = .018). 
 Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-1, neither CDS-1 (∆R2 = 0.0%; F = 0.5; df = 1, 8697; p 
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= .46) nor CDS-2 (∆R2 = 0.0%; F = 0.8; df = 1, 8697; p = .37) explained a significant 
proportion of the variance in one-year healthcare expenditures. 
 Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-2, neither CDS-1 (∆R2 = 0.0%; F = 0.4; df = 1, 8697; p 
= .53) nor CDS-2 (∆R2 = 0.01%; F = 2.0; df = 1, 8697; p = .16) explained a significant 
portion of the variance in one-year healthcare expenditures. 
 Table 3.2.1 summarizes the results from section 3.2.1. 
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Table 3.2.1: Linear Regression Modeling Results: Prediction of Total Healthcare Expenditures in the One-Year Post-Index 
Period 
Models R2 Difference Tests 
No. Predictors Adj. R2 (%) ∆R2 (%) F value d.f. p value 
 Baseline model: model 1 
1 Age + Sex 0.26 -- -- -- -- 
2 Age + Sex + # of Meds 7.49 7.23 681.0 1, 8700 < 0.0001 
3 Age + Sex + Index-year Expenditures 35.62 35.36 4778.9 1, 8700 < 0.0001 
4 Age + Sex + CCI-1 11.26 11.00 1079.8 1, 8700 < 0.0001 
5 Age + Sex + CCI-2 11.54 11.28 1110.9 1, 8700 < 0.0001 
6 Age + Sex + CDS-1 3.89 3.63 329.4 1, 8700 < 0.0001 
7 Age + Sex + CDS-2 5.54 5.28 487.7 1, 8700 < 0.0001 
 Baseline model: model 8 
8 Age + Sex + # of Meds + Index-year Expenditures 36.43 -- -- -- -- 
9 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 37.23 0.80 112.1 1, 8698 < 0.0001 
10 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 36.96 0.53 74.2 1, 8698 < 0.0001 
11 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 36.46 0.03 4.6 1, 8698 0.032 
12 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 36.46 0.03 5.6 1, 8698 0.018 
 Baseline model: model 9 
13 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 37.23 0.00 0.5 1, 8697 0.46 
14 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 37.23 0.00 0.8 1, 8697 0.37 
 Baseline model: model 10 
15 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 36.96 0.00 0.4 1, 8697 0.53 
16 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 36.97 0.01 2.0 1, 8697 0.16 
# of Meds: number of distinct medications; Adj. R2: adjusted R2 ; ∆R2 : difference in R2 ; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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3.2.2 One-year High Healthcare Expenditures – Logistic Regression Models: 
 
 In predicting one-year high (≥ 90th percentile) healthcare expenditures, the index-
year healthcare expenditures had the highest predictive power (c = .810), followed by the 
number of distinct medications (c = .767), CCI-2 (c = .749), CDS-2 (c = .737), CCI-1 (c 
= .735), and CDS-1 (c = .719), where age and sex were included in the models. Results 
from the Hosmer-Lemeshow goodness-of-fit tests indicated good model fit only for the 
model that included the number of distinct medications (χ² = 4.8; df = 8; p = .78) but poor 
model fits for the models that included the index-year total healthcare expenditures (χ² = 
141.9; df = 8; p < .0001), CCI-1 (χ² = 26.1; df = 8; p = .0010), CCI-2 (χ² = 16.0; df = 8; p 
= .042), CDS-1 (χ² = 28.1; df = 8; p = .0005), and CDS-2 (χ² = 58.3; df = 8; p < .0001). 
 With the inclusion of age, sex, number of distinct medications, and index-year 
total healthcare expenditures in the models, adding the CCI-1 or CCI-2 produced the 
same predictive power (c = .813). With the inclusion of age, sex, number of distinct 
medications, and index-year total healthcare expenditures in the models, adding the CDS-
1 or CDS-2 produced similar predictive power (c = .808 for CDS-1; c = .809 for CDS-2). 
Results from the Hosmer-Lemeshow goodness-of-fit tests indicated good model fit for 
the models that included the CCI-1 (χ² = 10.7; df = 8; p = .22), CCI-2 (χ² = 10.5; df = 8; p 
= .23), and CDS-1 (χ² = 10.6; df = 8; p = .23); however, the fit was poor for the model 
that included the CDS-2 (χ² = 21.7; df = 8; p = .0054) 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-1, and CDS-1 produced a c statistic of .813, with good 
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model fit (χ² = 9.0; df = 8; p = .35). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-1, and CDS-2 produced a c statistic 
of .814, with good model fit (χ² = 9.5; df = 8; p = .30). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-2, and CDS-1 produced a c statistic of .812, with good 
model fit (χ² = 9.9; df = 8; p = .27). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-2, and CDS-2 produced a c statistic 
of .813, with good model fit (χ² = 12.1; df = 8; p = .15). 
 Table 3.2.2 summarizes the results from section 3.2.2.
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Table 3.2.2: Logistic Regression Modeling Results: Prediction of High (≥ 90th Percentile) Healthcare Expenditures in the One-
Year Post-Index Period 
Models Hosmer-Lemeshow Tests 
No. Predictors c statistic χ² d.f. p value 
17 Age + Sex 0.575 4.7 0.79 
18 Age + Sex + # of Meds 0.767 4.8 0.78 
19 Age + Sex + Index-year Expenditures 0.810 141.9 < 0.0001 
20 Age + Sex + CCI-1 0.735 26.1 0.0010 
21 Age + Sex + CCI-2 0.749 16.0 0.042 
22 Age + Sex + CDS-1 0.719 28.1 0.0005 
23 Age + Sex + CDS-2 0.737 58.3 < 0.0001 
24 Age + Sex + # of Meds + Index-year Expenditures 0.807 11.7 0.16 
25 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 0.813 10.7 0.22 
26 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 0.813 10.5 0.23 
27 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 0.808 10.6 0.23 
28 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 0.809 21.7 0.0054 
29 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 0.813 9.0 0.35 
30 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 0.814 9.5 0.30 
31 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 0.812 9.9 0.27 
32 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 0.813 12.1 
8 
0.15 
# of Meds: number of distinct medications; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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3.2.3 Two-year Total healthcare Expenditures – Linear Regression Models: 
 
Controlling for age and sex, all six predictors produced significant increases of 
variance explained in two-year total healthcare expenditures: the number of distinct 
medications added an additional 8.0% of the variance (F = 757.6; df = 1, 8700; p < 
.0001); the index-year total healthcare expenditures added an additional 31.2% of the 
variance (F = 3971.6; df = 1, 8700; p < .0001); CCI-1 added an additional 11.7% of the 
variance (F = 1152.2; df = 1, 8700; p < .0001); CCI-2 added an additional 12.0% of the 
variance (F = 1191.1; df = 1, 8700; p < .0001); CDS-1 added an additional 4.1% of the 
variance (F = 370.6; df = 1, 8700; p < .0001); and CDS-2 added an additional 5.7% of the 
variance (F = 529.5; df = 1, 8700; p < .0001). 
 Controlling for age, sex, number of distinct medications, and index-year total 
healthcare expenditures, the four comorbidity adjustment measures contributed 
significant proportions of the variance in two-year total healthcare expenditures: 
including CCI-1 increased the variance explained by 1.2% (F = 154.3; df = 1, 8698; p < 
.0001); including CCI-2 increased the variance explained by 0.8% (F = 110.8; df = 1, 
8698; p < .0001); including CDS-1 increased the variance explained by 0.04% (F = 5.7; 
df = 1, 8698; p = .017); and including CDS-2 increased the variance explained by 0.05% 
(F = 7.5; df = 1, 8698; p = .063). 
 Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-1, neither CDS-1 (∆R2 = 0.0%; F = 0.5; df = 1, 8697; p 
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= .46) nor CDS-2 (∆R2 = 0.0%; F = 1.0; df = 1, 8697; p = .31) explained a significant 
portion of the variance in two-year healthcare expenditures. 
 Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-2, neither CDS-1 (∆R2 = -0.01%; F = 0.3; df = 1, 8697; 
p = .59) nor CDS-2 (∆R2 = 0.0%; F = 2.5; df = 1, 8697; p = .11) explained a significant 
portion of the variance in two-year healthcare expenditures. 
 Table 3.2.3 summarizes the results from section 3.2.3.
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Table 3.2.3: Linear Regression Modeling Results: Prediction of Total Healthcare Expenditures in the Two-Year Post-Index 
Period 
Models R2 Difference Tests 
No. Predictors Adj. R2 (%) ∆R2 (%) F value d.f. p value 
 Baseline model: model 33 
33 Age + Sex 0.32 -- -- -- -- 
34 Age + Sex + # of Meds 8.29 7.97 757.6 1, 8700 < 0.0001 
35 Age + Sex + Index-year Expenditures 31.55 31.23 3971.0 1, 8700 < 0.0001 
36 Age + Sex + CCI-1 11.97 11.65 1152.2 1, 8700 < 0.0001 
37 Age + Sex + CCI-2 12.31 11.99 1191.1 1, 8700 < 0.0001 
38 Age + Sex + CDS-1 4.38 4.06 370.6 1, 8700 < 0.0001 
39 Age + Sex + CDS-2 6.03 5.71 529.5 1, 8700 < 0.0001 
 Baseline model: model 40 
40 Age + Sex + # of Meds + Index-year Expenditures 32.90 -- -- -- -- 
41 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 34.06 1.16 154.3 1, 8698 < 0.0001 
42 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 33.74 0.84 110.8 1, 8698 < 0.0001 
43 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 32.94 0.04 5.7 1, 8698 0.017 
44 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 32.95 0.05 7.5 1, 8698 0.063 
 Baseline model: model 41 
45 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 34.06 0.00 0.5 1, 8697 0.46 
46 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 34.06 0.00 1.0 1, 8697 0.31 
 Baseline model: model 42 
47 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 33.73 -0.01 0.3 1, 8697 0.59 
48 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 33.75 0.01 2.5 1, 8697 0.11 
# of Meds: number of distinct medications; Adj. R2: adjusted R2 ; ∆R2 : difference in R2 ; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95. 
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3.2.4 Two-year High Healthcare Expenditures – Logistic Regression Models: 
 
 In predicting two-year high (≥ 90th percentile) healthcare expenditures, the index-
year healthcare expenditures had the highest predictive power (c = .823), followed by the 
number of distinct medications (c = .771), CCI-2 (c = .754), CDS-2 (c = .744), CCI-1 (c 
= .737), and CDS-1 (c = .720), where age and sex were included in the models. Results 
from the Hosmer-Lemeshow goodness-of-fit tests indicated good model fit only for the 
model that included the number of distinct medications (χ² = 4.0; df = 8; p = .85), but 
poor model fits for the models that included the index-year total healthcare expenditures 
(χ² = 166.6; df = 8; p < .0001), CCI-1 (χ² = 19.3; df = 8; p = .013), CCI-2 (χ² = 16.7; df = 
8; p = .033), CDS-1 (χ² = 30.0; df = 8; p = .0002), and CDS-2 (χ² = 76.5; df = 8; p < 
.0001). 
 With the inclusion of age, sex, number of distinct medications, and index-year 
total healthcare expenditures in the models, adding the CCI-1 or CCI-2 produced the 
same predictive power (c = .823). With the inclusion of age, sex, number of distinct 
medications, and index-year total healthcare expenditures in the models, adding the CDS-
1 or CDS-2 produced similar predictive power (c = .817 for CDS-1; c = .820 for CDS-2). 
Results from the Hosmer-Lemeshow goodness-of-fit tests indicated poor model fit for all 
four models: the χ² was 17.6 for CCI-1 (df = 8; p = .024), 13.7 for CCI-2 (df = 8; p = 
.090), 19.4 for CDS-1 (df = 8; p = .013), and 24.6 for CDS-2 (df = 8; p = .0018). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-1, and CDS-1 produced a c statistic of .823, with good 
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model fit (χ² = 13.0; df = 8; p = .11). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-1, and CDS-2 produced a c statistic 
of .824, with poor model fit (χ² = 16.1; df = 8; p = .041). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-2, and CDS-1 produced a c statistic of .823, with good 
model fit (χ² = 12.1; df = 8; p = .15). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-2, and CDS-2 produced a c statistic 
of .824, with good model fit (χ² = 13.1; df = 8; p = .11). 
 Table 3.2.4 summarizes the results from section 3.2.4.
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Table 3.2.4: Logistic Regression Modeling Results: Prediction of High (≥ 90th Percentile) Healthcare Expenditures in the Two-
Year Post-Index Period 
Models Hosmer-Lemeshow Tests 
No. Predictors c statistic χ² d.f. p value 
49 Age + Sex 0.575 7.5 0.49 
50 Age + Sex + # of Meds 0.771 4.0 0.85 
51 Age + Sex + Index-year Expenditures 0.823 166.6 < 0.0001 
52 Age + Sex + CCI-1 0.737 19.3 0.013 
53 Age + Sex + CCI-2 0.754 16.7 0.033 
54 Age + Sex + CDS-1 0.720 30.0 0.0002 
55 Age + Sex + CDS-2 0.744 76.5 < 0.0001 
56 Age + Sex + # of Meds + Index-year Expenditures 0.818 27.3 0.0006 
57 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 0.823 17.6 0.024 
58 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 0.823 13.7 0.090 
59 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 0.817 19.4 0.013 
60 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 0.820 24.6 0.018 
61 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 0.823 13.0 0.11 
62 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 0.824 16.1 0.041 
63 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 0.823 12.1 0.15 
64 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 0.824 13.1 
8 
0.11 
# of Meds: number of distinct medications; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
 
99 
3.3 MODELING RESULTS: PREDICTION OF NUMBER AND RISK OF HOSPITALIZATIONS 
3.3.1 One-year Number of Hospitalizations – Linear Regression Models: 
 
Controlling for age and sex, all six predictors produced significant increases of 
variance explained in one-year number of hospitalizations: the number of distinct 
medications added an additional 6.0% of the variance (F = 553.0; df = 1, 8700; p < 
.0001); the index-year total healthcare expenditures added an additional 6.5% of the 
variance (F = 605.5; df = 1, 8700; p < .0001); CCI-1 added an additional 6.6% of the 
variance (F = 619.2; df = 1, 8700; p < .0001); CCI-2 added an additional 7.8% of the 
variance (F = 739.3; df = 1, 8700; p < .0001); CDS-1 added an additional 2.8% of the 
variance (F = 254.5; df = 1, 8700; p < .0001); and CDS-2 added an additional 3.5% of the 
variance (F = 314.3; df = 1, 8700; p < .0001). 
 Controlling for age, sex, number of distinct medications, and index-year total 
healthcare expenditures, adding the CCI-1 increased the variance explained by 1.6% (F = 
156.8; df = 1, 8698; p < .0001), while adding the CCI-2 increased the variance explained 
by 1.8% (F = 176.8; df = 1, 8698; p < .0001). Including the CDS-1 in the model 
decreased the variance explained (∆R2 = -0.01%; F = .8; df = 1, 8698; p = .38), and 
including the CDS-2 increased the variance explained marginally (∆R2 = 0.01%; F = 2.2; 
df = 1, 8698; p = .14); however, neither results was significant statistically. 
Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-1, neither CDS-1 (∆R2 = 0.0%; F = .7; df = 1, 8697; p = 
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.42) nor CDS-2 (∆R2 = -0.01%; F = .1; df = 1, 8697; p = .80) explained a significant 
portion of the variance in one-year number of hospitalizations. 
Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-2, neither CDS-1 (∆R2 = 0.02%; F = 2.2; df = 1, 8697; 
p = .14) nor CDS-2 (∆R2 = -0.01%; F = 0; df = 1, 8697; p = .97) explained a significant 
portion of the variance in one-year number of hospitalizations. 
Table 3.3.1 summarizes results from section 3.3.1.
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Table 3.3.1: Linear Regression Modeling Results: Prediction of Number of Hospitalizations in the One-Year Post-Index Period 
Models R2 Difference Tests 
No. Predictors Adj. R2 (%) ∆R2 (%) F value d.f. p value 
 Baseline model: model 66 
65 Age + Sex 0.25 -- -- -- -- 
66 Age + Sex + # of Meds 6.20 5.95 553.0 1, 8700 < 0.0001 
67 Age + Sex + Index-year Expenditures 6.74 6.49 605.5 1, 8700 < 0.0001 
68 Age + Sex + CCI-1 6.87 6.62 619.2 1, 8700 < 0.0001 
69 Age + Sex + CCI-2 8.05 7.80 739.3 1, 8700 < 0.0001 
70 Age + Sex + CDS-1 3.07 2.82 254.5 1, 8700 < 0.0001 
71 Age + Sex + CDS-2 3.72 3.47 314.3 1, 8700 < 0.0001 
 Baseline model: model 72 
72 Age + Sex + # of Meds + Index-year Expenditures 9.76 -- -- -- -- 
73 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 11.34 1.58 156.8 1, 8698 < 0.0001 
74 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 11.54 1.78 176.8 1, 8698 < 0.0001 
75 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 9.75 -0.01 0.8 1, 8698 0.38 
76 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 9.77 0.01 2.2 1, 8698 0.14 
 Baseline model: model 73 
77 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 11.34 0.00 0.7 1, 8697 0.42 
78 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 11.33 -0.01 0.1 1, 8697 0.80 
 Baseline model: model 74 
79 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 11.56 0.02 2.2 1, 8697 0.14 
80 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 11.53 -0.01 0.0 1, 8697 0.97 
# of Meds: number of distinct medications; Adj. R2: adjusted R2 ; ∆R2 : difference in R2 ; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95. 
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3.3.2 One-year Risk of Hospitalization – Logistic Regression Models: 
 
 In predicting one-year risk of hospitalization, the index-year healthcare 
expenditures had the highest predictive power (c = .684), followed by the number of 
distinct medications (c = .677), CCI-2 (c = .658), CDS-2 (c = .649), CCI-1 (c = .645), and 
CDS-1 (c = .635), where age and sex were included in the models. Results from the 
Hosmer-Lemeshow goodness-of-fit tests indicated good model fit for the models that 
included the number of distinct medications (χ² = 9.1; df = 8; p = .34) and CCI-1 (χ² = 
10.6; df = 8; p = .22), but poor model fits for the models that included the index-year total 
healthcare expenditures (χ² = 118.4; df = 8; p < .0001), CCI-2 (χ² = 16.7; df = 8; p = 
.033), CDS-1 (χ² = 16.2; df = 8; p = .040), and CDS-2 (χ² = 42.3; df = 8; p < .0001). 
 With the inclusion of age, sex, number of distinct medications, and index-year 
total healthcare expenditures in the models, both CCI-1 and CCI-2 had the same 
predictive power (c = .701), and both CDS-1 and CDS-2 had the same predictive power 
(c = .692). Results from the Hosmer-Lemeshow goodness-of-fit tests indicated good 
model fit for all four models: the χ² was 7.6 for CCI-1 (df = 8; p = .47), 8.2 for CCI-2 (df 
= 8; p = .41), 9.7 for CDS-1 (df = 8; p = .29), and 8.6 for CDS-2 (df = 8; p = .37). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-1, and CDS-1 produced a c statistic of .700, with good 
model fit (χ² = 10.4; df = 8; p = .24). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-1, and CDS-2 produced a c statistic 
of .701, with good model fit (χ² = 6.2; df = 8; p = .62). 
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 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-2, and CDS-1 produced a c statistic of .701, with good 
model fit (χ² = 7.2; df = 8; p = .52). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-2, and CDS-2 also produced a c 
statistic of .701, with good model fit (χ² = 10.1; df = 8; p = .26). 
 Table 3.3.2 summarizes the results from section 3.3.2.
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Table 3.3.2: Logistic Regression Modeling Results: Prediction of Risk (≥ 1 Admission) of Hospitalizations in the One-Year 
Post-Index Period 
Models Hosmer-Lemeshow Tests 
No. Predictors c statistic χ² d.f. p value 
81 Age + Sex 0.545 30.3 0.0002 
82 Age + Sex + # of Meds 0.677 9.1 0.34 
83 Age + Sex + Index-year Expenditures 0.684 118.4 < 0.0001 
84 Age + Sex + CCI-1 0.645 10.6 0.22 
85 Age + Sex + CCI-2 0.658 16.7 0.033 
86 Age + Sex + CDS-1 0.635 16.2 0.040 
87 Age + Sex + CDS-2 0.649 42.3 < 0.0001 
88 Age + Sex + # of Meds + Index-year Expenditures 0.692 11.4 0.18 
89 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 0.701 7.6 0.47 
90 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 0.701 8.2 0.41 
91 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 0.692 9.7 0.29 
92 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 0.692 8.6 0.37 
93 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 0.700 10.4 0.24 
94 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 0.701 6.2 0.62 
95 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 0.701 7.2 0.52 
96 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 0.701 10.1 
8 
0.26 
# of Meds: number of distinct medications; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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3.3.3 Two-year Number of Hospitalizations – Linear Regression Models: 
 
Controlling for age and sex, all six predictors produced significant increases of 
variance explained in two-year number of hospitalizations: the number of distinct 
medications added an additional 7.4% of the variance (F = 693.0; df = 1, 8700; p < 
.0001); the index-year total healthcare expenditures added an additional 7.0% of the 
variance (F = 656.1; df = 1, 8700; p < .0001); CCI-1 added an additional 7.8% of the 
variance (F = 736.5; df = 1, 8700; p < .0001); CCI-2 added an additional 9.0% of the 
variance (F = 860.5; df = 1, 8700; p < .0001); CDS-1 added an additional 3.4% of the 
variance (F = 303.6; df = 1, 8700; p < .0001); and CDS-2 added an additional 4.6% of the 
variance (F = 419.5; df = 1, 8700; p < .0001). 
Controlling for age, sex, number of distinct medications, and index-year total 
healthcare expenditures, adding the CCI-1 increased the variance explained by 1.9% (F = 
192.4; df = 1, 8698; p < .0001), adding the CCI-2 increased the variance explained by 
2.0% (F = 203.1; df = 1, 8698; p < .0001), and adding the CDS-2 increased the variance 
explained by 0.07% (F = 7.8; df = 1, 8698; p = .0054); however, adding the CDS-1 
decreased the variance explained by 0.01% (F = .3; df = 1, 8698; p = .62). 
Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-1, neither CDS-1 (∆R2 = 0.01%; F = 1.9; df = 1, 8697; 
p = .17) nor CDS-2 (∆R2 = 0.0%; F = .8; df = 1, 8697; p = .38) explained a significant 
portion of the variance in two-year number of hospitalizations. 
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Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-2, CDS-1 explained a significant portion of the 
variance in two-year number of hospitalizations (∆R2 = 0.04%; F = 4.2; df = 1, 8697; p = 
.040), but CDS-2 did not (∆R2 = 0.0%; F = 1.5; df = 1, 8697; p = .21)  
Table 3.3.3 summarizes the results from section 3.3.3.
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Table 3.3.3: Linear Regression Modeling Results: Prediction of Number of Hospitalizations in the Two-Year Post-Index 
Period 
Models R2 Difference Tests 
No. Predictors Adj. R2 (%) ∆R2 (%) F value d.f. p value 
 Baseline model: model 97 
97 Age + Sex 0.29 -- -- -- -- 
98 Age + Sex + # of Meds 7.64 7.35 693.0 1, 8700 < 0.0001 
99 Age + Sex + Index-year Expenditures 7.28 6.99 656.1 1, 8700 < 0.0001 
100 Age + Sex + CCI-1 8.06 7.77 736.5 1, 8700 < 0.0001 
101 Age + Sex + CCI-2 9.26 8.97 860.5 1, 8700 < 0.0001 
102 Age + Sex + CDS-1 3.64 3.35 303.6 1, 8700 < 0.0001 
103 Age + Sex + CDS-2 4.87 4.58 419.5 1, 8700 < 0.0001 
 Baseline model: model 104 
104 Age + Sex + # of Meds + Index-year Expenditures 11.25 -- -- -- -- 
105 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 13.16 1.91 192.4 1, 8698 < 0.0001 
106 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 13.26 2.01 203.1 1, 8698 < 0.0001 
107 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 11.24 -0.01 0.3 1, 8698 0.62 
108 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 11.32 0.07 7.8 1, 8698 0.0054 
 Baseline model: model 105 
109 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 13.17 0.01 1.9 1, 8697 0.17 
110 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 13.16 0.00 0.8 1, 8697 0.38 
 Baseline model: model 106 
111 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 13.30 0.04 4.2 1, 8697 0.040 
112 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 13.27 0.01 1.5 1, 8697 0.21 
# of Meds: number of distinct medications; Adj. R2: adjusted R2 ; ∆R2 : difference in R2 ; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95. 
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3.3.4 Two-year Risk of Hospitalization – Logistic Regression Models: 
 
 In predicting two-year risk of hospitalization, the index-year healthcare 
expenditures had the highest predictive power (c = .676), followed by the number of 
distinct medications (c = .663), CCI-2 (c = .642), CDS-2 (c = .638), CCI-1 (c = .631), and 
CDS-1 (c = .619), where age and sex were included in the models. Results from the 
Hosmer-Lemeshow goodness-of-fit tests indicated good model fit for the model that 
included the number of distinct medications (χ² = 12.2; df = 8; p = .14), but poor model 
fits for the models that included the index-year total healthcare expenditures (χ² = 136.2; 
df = 8; p < .0001), CCI-1 (χ² = 21.3; df = 8; p = .0065), CCI-2 (χ² = 20.2; df = 8; p = 
.0095), CDS-1 (χ² = 19.1; df = 8; p = .014), and CDS-2 (χ² = 59.5; df = 8; p < .0001). 
 With the inclusion of age, sex, number of distinct medications, and index-year 
total healthcare expenditures in the models, the CCI-1 (c = .689) and CCI-2 (c = .688) 
had similar predictive power, and the CDS-1 and CDS-2 had similar predictive power (c 
= .681 for CDS-1; c = .682 for CDS-2). Results from the Hosmer-Lemeshow goodness-
of-fit tests indicated good model fit for the model including CCI-2 (χ² = 11.2; df = 8; p = 
.19) but poor model fit for the models that included CCI-1 (χ² = 16.9; df = 8; p = .031), 
CDS-1 (χ² = 18.4; df = 8; p = .019), and CDS-2 (χ² = 17.0; df = 8; p = .030). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-1, and CDS-1 produced a c statistic of .689, with poor 
model fit (χ² = 17.4; df = 8; p = .026). The model that included age, sex, number of 
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distinct medications, index-year healthcare expenditures, CCI-1, and CDS-2 also 
produced a c statistic of .689, with poor model fit (χ² = 15.6; df = 8; p = .049). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-2, and CDS-1 produced a c statistic of .688, with good 
model fit (χ² = 11.9; df = 8; p = .16). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-2, and CDS-2 also produced a c 
statistic of .688, with good model fit (χ² = 11.4; df = 8; p = .18). 
 Table 3.3.4 summarizes the results from section 3.3.4.
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Table 3.3.4: Logistic Regression Modeling Results: Prediction of Risk (≥ 1 Admission) of Hospitalizations in the Two-Year 
Post-Index Period 
Models Hosmer-Lemeshow Tests 
No. Predictors c statistic χ² d.f. p value 
113 Age + Sex 0.538 54.9 < 0.0001 
114 Age + Sex + # of Meds 0.663 12.2 0.14 
115 Age + Sex + Index-year Expenditures 0.676 136.2 < 0.0001 
116 Age + Sex + CCI-1 0.631 21.3 0.0065 
117 Age + Sex + CCI-2 0.642 20.2 0.0095 
118 Age + Sex + CDS-1 0.619 19.1 0.014 
119 Age + Sex + CDS-2 0.638 59.5 < 0.0001 
120 Age + Sex + # of Meds + Index-year Expenditures 0.681 18.1 0.020 
121 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 0.689 16.9 0.031 
122 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 0.688 11.2 0.19 
123 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 0.681 18.4 0.019 
124 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 0.682 17.0 0.030 
125 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 0.689 17.4 0.026 
126 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 0.689 15.6 0.049 
127 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 0.688 11.9 0.16 
128 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 0.688 11.4 
8 
0.18 
# of Meds: number of distinct medications; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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3.4 MODELING RESULTS: PREDICTION OF NUMBER AND RISK OF EMERGENCY 
DEPARTMENT VISITS 
3.4.1 One-year number of emergency department visits – linear regression models: 
 
Controlling for age and sex, all six predictors produced significant increases of 
variance explained in one-year number of emergency department visits: the number of 
distinct medications added an additional 8.5% of the variance (F = 825.2; df = 1, 8700; p 
< .0001); the index-year total healthcare expenditures added an additional 4.8% of the 
variance (F = 446.7; df = 1, 8700; p < .0001); CCI-1 added an additional 4.5% of the 
variance (F = 420.6; df = 1, 8700; p < .0001); CCI-2 added an additional 5.8% of the 
variance (F = 546.9; df = 1, 8700; p < .0001); CDS-1 added an additional 3.2% of the 
variance (F = 290.5; df = 1, 8700; p < .0001); and CDS-2 added an additional 5.2% of the 
variance (F = 486.6; df = 1, 8700; p < .0001). 
 Controlling for age, sex, number of distinct medications, and index-year total 
healthcare expenditures, adding the CCI-1 increased the variance explained by 0.5% (F = 
51.2; df = 1, 8698; p < .0001), while adding the CCI-2 increased the variance explained 
by 0.6% (F = 61.5; df = 1, 8698; p < .0001); adding the CDS-1 increased the variance 
explained by 0.03% (F = 4.1; df = 1, 8698; p = .042) and adding the CDS-2 increased the 
variance explained by 0.1% (F = 11.0; df = 1, 8698; p = .0009). 
Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-1, both CDS-1 (∆R2 = 0.08%; F = 9.2; df = 1, 8697; p = 
.0024) and CDS-2 (∆R2 = 0.05%; F = 5.5; df = 1, 8697; p = .019) explained significant 
portions of the variance in one-year number of emergency department visits. 
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Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-2, both CDS-1 (∆R2 = 0.11%; F = 12.1; df = 1, 8697; p 
= .0005) and CDS-2 (∆R2 = 0.10%; F = 6.1; df = 1, 8697; p = .013) explained significant 
portions of the variance in one-year number of emergency department visits. 
Table 3.4.1 summarizes the results from section 3.4.1.
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Table 3.4.1: Linear Regression Modeling Results: Prediction of Number of Emergency Department Visits in the One-Year 
Post-Index Period 
Models R2 Difference Tests 
No. Predictors Adj. R2 (%) ∆R2 (%) F value d.f. p value 
 Baseline model: model 129 
129 Age + Sex 1.35 -- -- -- -- 
130 Age + Sex + # of Meds 9.89 8.54 825.2 1, 8700 < 0.0001 
131 Age + Sex + Index-year Expenditures 6.16 4.81 446.7 1, 8700 < 0.0001 
132 Age + Sex + CCI-1 5.89 4.54 420.6 1, 8700 < 0.0001 
133 Age + Sex + CCI-2 7.18 5.83 546.9 1, 8700 < 0.0001 
134 Age + Sex + CDS-1 4.53 3.18 290.5 1, 8700 < 0.0001 
135 Age + Sex + CDS-2 6.57 5.22 486.6 1, 8700 < 0.0001 
 Baseline model: model 136 
136 Age + Sex + # of Meds + Index-year Expenditures 11.74 -- -- -- -- 
137 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 12.24 0.50 51.2 1, 8698 < 0.0001 
138 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 12.35 0.61 61.5 1, 8698 < 0.0001 
139 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 11.77 0.03 4.1 1, 8698 0.042 
140 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 11.84 0.10 11.0 1, 8698 0.0009 
 Baseline model: model 137 
141 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 12.32 0.08 9.2 1, 8697 0.0024 
142 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 12.29 0.05 5.5 1, 8697 0.019 
 Baseline model: model 138 
143 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 12.46 0.11 12.1 1, 8697 0.0005 
144 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 12.45 0.10 6.1 1, 8697 0.013 
# of Meds: number of distinct medications; Adj. R2: adjusted R2 ; ∆R2 : difference in R2 ; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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3.4.2 One-year Risk of Emergency Department Visit – Logistic Regression Models: 
 
 In predicting one-year risk of emergency department visit, the number of distinct 
medications had the highest predictive power (c = .653), followed by CDS-2 (c = .624), 
CCI-2 (c = .621), CDS-1 (c = .619), index-year healthcare expenditures (c = .617), and 
CCI-1 (c = .614), where age and sex were included in the models. Results from the 
Hosmer-Lemeshow goodness-of-fit tests indicated good model fit for the models that 
included the number of distinct medications (χ² = 7.2; df = 8; p = .51), CCI-1 (χ² = 3.5; df 
= 8; p = .90), CCI-2 (χ² = 6.1; df = 8; p = .64), CDS-1 (χ² = 5.2; df = 8; p = .74), and 
CDS-2 (χ² = 15.1; df = 8; p = .057), but poor model fit for the model that included the 
index-year total healthcare expenditures (χ² = 39.7; df = 8; p = < .0001). 
 With the inclusion of age, sex, number of distinct medications, and index-year 
total healthcare expenditures in the models, the CCI-1 produced a c statistic of .659 and 
the CCI-2 produced a c statistic of .660; the CDS-1 and CDS-2 both produced a c statistic 
of .656. Results from the Hosmer-Lemeshow goodness-of-fit tests indicated good model 
fit for all four models: the χ² was 13.6 for CCI-1 (df = 8; p = .092), 10.9 for CCI-2 (df = 
8; p = .21), 6.7 for CDS-1 (df = 8; p = .56), and 9.4 for CDS-2 (df = 8; p = .31). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-1, and CDS-1 produced a c statistic of .659, with good 
model fit (χ² = 12.3; df = 8; p = .14). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-1, and CDS-2 produced a c statistic 
of .660, with good model fit (χ² = 11.2; df = 8; p = .19). 
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 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-2, and CDS-1 produced a c statistic of .660, with good 
model fit (χ² = 11.3; df = 8; p = .18). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-2, and CDS-2 also produced a c 
statistic of .660, with good model fit (χ² = 9.4; df = 8; p = .31). 
 Table 3.4.2 summarizes the results from section 3.4.2.
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Table 3.4.2: Logistic Regression Modeling Results: Prediction of Risk (≥ 1 Visit) of Emergency Department Visits in the One-
Year Post-Index Period 
Models Hosmer-Lemeshow Tests 
No. Predictors c statistic χ² d.f. p value 
145 Age + Sex 0.563 10.3 0.24 
146 Age + Sex + # of Meds 0.653 7.2 0.51 
147 Age + Sex + Index-year Expenditures 0.617 39.7 < 0.0001 
148 Age + Sex + CCI-1 0.614 3.5 0.90 
149 Age + Sex + CCI-2 0.621 6.1 0.64 
150 Age + Sex + CDS-1 0.619 5.2 0.74 
151 Age + Sex + CDS-2 0.624 15.1 0.057 
152 Age + Sex + # of Meds + Index-year Expenditures 0.656 7.0 0.54 
153 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 0.659 13.6 0.092 
154 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 0.660 10.9 0.21 
155 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 0.656 6.7 0.56 
156 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 0.656 9.4 0.31 
157 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 0.659 12.3 0.14 
158 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 0.660 11.2 0.19 
159 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 0.660 11.3 0.18 
160 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 0.660 9.4 
8 
0.31 
# of Meds: number of distinct medications; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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3.4.3 Two-year Number of Emergency Department Visits – Linear Regression 
Models: 
 
Controlling for age and sex, all six predictors produced significant increases of 
variance explained in two-year number of emergency department visits: the number of 
distinct medications added an additional 10.3% of the variance (F = 1024.5; df = 1, 8700; 
p < .0001); the index-year total healthcare expenditures added an additional 5.2% of the 
variance (F = 487.2; df = 1, 8700; p < .0001); CCI-1 added an additional 5.4% of the 
variance (F = 504.1; df = 1, 8700; p < .0001); CCI-2 added an additional 6.7% of the 
variance (F = 639.6; df = 1, 8700; p < .0001); CDS-1 added an additional 4.0% of the 
variance (F = 373.6; df = 1, 8700; p < .0001); and CDS-2 added an additional 6.5% of the 
variance (F = 616.8; df = 1, 8700; p < .0001). 
Controlling for age, sex, number of distinct medications, and index-year total 
healthcare expenditures, adding the CCI-1 increased the variance explained by 0.6% (F = 
65.8; df = 1, 8698; p < .0001), and adding the CCI-2 increased the variance explained by 
0.7% (F = 71.1; df = 1, 8698; p < .0001), and adding the CDS-2 increased the variance 
explained by 0.2% (F = 18.5; df = 1, 8698; p = < .0001); however, inclusion of the CDS-
1 did not increase the variance explained significantly (∆R2 = 0.02%; F = 2.7; df = 1, 
8698; p = .10). 
Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-1, both CDS-1 (∆R2 = 0.07%; F = 7.7; df = 1, 8697; p = 
.0056) and CDS-2 (∆R2 = 0.09%; F = 10.3; df = 1, 8697; p = .0014) explained significant 
portions of the variance in two-year number of emergency department visits. 
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Controlling for age, sex, number of distinct medications, index-year total 
healthcare expenditures, and CCI-2, both CDS-1 (∆R2 = 0.1%; F = 10.2; df = 1, 8697; p = 
.0014) and CDS-2 (∆R2 = 0.1%; F = 11.6; df = 1, 8697; p = .0007) explained significant 
portions of the variance in two-year number of emergency department visits. 
Table 3.4.3 summarizes the results from section 3.4.3.
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Table 3.4.3: Linear Regression Modeling Results: Prediction of Number of Emergency Department Visits in the Two-Year 
Post-Index Period 
Models R2 Difference Tests 
No. Predictors Adj. R2 (%) ∆R2 (%) F value d.f. p value 
 Baseline model: model 161 
161 Age + Sex 2.14 -- -- -- -- 
162 Age + Sex + # of Meds 12.44 10.30 1024.5 1, 8700 < 0.0001 
163 Age + Sex + Index-year Expenditures 7.32 5.18 487.2 1, 8700 < 0.0001 
164 Age + Sex + CCI-1 7.49 5.35 504.1 1, 8700 < 0.0001 
165 Age + Sex + CCI-2 8.83 6.69 639.6 1, 8700 < 0.0001 
166 Age + Sex + CDS-1 6.16 4.02 373.6 1, 8700 < 0.0001 
167 Age + Sex + CDS-2 8.61 6.47 616.8 1, 8700 < 0.0001 
 Baseline model: model 168 
168 Age + Sex + # of Meds + Index-year Expenditures 14.27 -- -- -- -- 
169 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 14.90 0.63 65.8 1, 8698 < 0.0001 
170 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 14.95 0.68 71.1 1, 8698 < 0.0001 
171 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 14.29 0.02 2.7 1, 8698 0.10 
172 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 14.44 0.17 18.5 1, 8698 < 0.0001 
 Baseline model: model 169 
173 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 14.97 0.07 7.7 1, 8697 0.0056 
174 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 14.99 0.09 10.3 1, 8697 0.014 
 Baseline model: model 170 
175 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 15.04 0.09 10.2 1, 8697 0.0014 
176 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 15.06 0.11 11.6 1, 8697 0.0007 
# of Meds: number of distinct medications; Adj. R2: adjusted R2 ; ∆R2 : difference in R2 ; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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3.4.4 Two-year Risk of Emergency Department Visits – Logistic Regression Models: 
 
 In predicting two-year risk of emergency department visits, the number of distinct 
medications had the highest predictive power (c = .654), followed by CDS-2 (c = .626), 
index-year healthcare expenditures (c = .623), CCI-2 (c = .619), CDS-2 (c = .618), and 
CCI-1 (c = .611), where age and sex were included in the models. Results from the 
Hosmer-Lemeshow goodness-of-fit tests indicated good model fit for the models that 
included the number of distinct medications (χ² = 8.4; df = 8; p = .39), CCI-1 (χ² = 5.8; df 
= 8; p = .69), CCI-2 (χ² = 9.6; df = 8; p = .30), CDS-1 (χ² = 12.4; df = 8; p = .14), and 
CDS-2 (χ² = 8.2; df = 8; p = .42). The model that included the index-year total healthcare 
expenditures had poor model fit  (χ² = 18.5; df = 8; p = .018).  
 With the inclusion of age, sex, number of distinct medications, and index-year 
total healthcare expenditures in the models, the CCI-1 and CCI-2 produced a c statistic of 
.660, while the CDS-1 and CDS-2 produced a c statistic of .657. Results from the 
Hosmer-Lemeshow goodness-of-fit tests indicated poor model fit for the model that 
included the CCI-1 (χ² = 15.7; df = 8; p = .047). The fit was good for the models that 
included the CCI-2 (χ² = 12.0; df = 8; p = .15), CDS-1 (χ² = 4.9; df = 8; p = .76), and 
CDS-2 (χ² = 4.8; df = 8; p = .78). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-1, and CDS-1 produced a c statistic of .660, with poor 
model fit (χ² = 16.1; df = 8; p = .041). The model that included age, sex, number of 
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distinct medications, index-year healthcare expenditures, CCI-1, and CDS-2 produced a c 
statistic of .660, with good model fit (χ² = 8.0; df = 8; p = .43). 
 The model that included age, sex, number of distinct medications, index-year 
healthcare expenditures, CCI-2, and CDS-1 produced a c statistic of .660, with good 
model fit (χ² = 10.8; df = 8; p = .21). The model that included age, sex, number of distinct 
medications, index-year healthcare expenditures, CCI-2, and CDS-2 also produced a c 
statistic of .660, with good model fit (χ² = 8.3; df = 8; p = .41). 
 Table 3.4.4 summarizes the results from section 3.4.4.
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Table 3.4.4: Logistic Regression Modeling Results: Prediction of Risk (≥ 1 Visit) of Emergency Department Visits in the Two-
Year Post-Index Period 
Models Hosmer-Lemeshow Tests 
No. Predictors c statistic χ² d.f. p value 
177 Age + Sex 0.566 25.3 0.0014 
178 Age + Sex + # of Meds 0.654 8.4 0.39 
179 Age + Sex + Index-year Expenditures 0.623 18.5 0.018 
180 Age + Sex + CCI-1 0.611 5.8 0.69 
181 Age + Sex + CCI-2 0.619 9.6 0.30 
182 Age + Sex + CDS-1 0.618 12.4 0.14 
183 Age + Sex + CDS-2 0.626 8.2 0.42 
184 Age + Sex + # of Meds + Index-year Expenditures 0.657 3.6 0.89 
185 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 0.660 15.7 0.047 
186 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 0.660 12.0 0.15 
187 Age + Sex + # of Meds + Index-year Expenditures + CDS-1 0.657 4.9 0.76 
188 Age + Sex + # of Meds + Index-year Expenditures + CDS-2 0.657 4.8 0.78 
189 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-1 0.660 16.1 0.041 
190 Age + Sex + # of Meds + Index-year Expenditures + CCI-1 + CDS-2 0.660 8.0 0.43 
191 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-1 0.660 10.8 0.21 
192 Age + Sex + # of Meds + Index-year Expenditures + CCI-2 + CDS-2 0.660 8.3 
8 
0.41 
# of Meds: number of distinct medications; d.f.: degrees of freedom 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 
Journal of Clinical Epidemiology 61, no. 12 (2008): 1234-40. 
CDS-1 is based on Von Korff M, et al. "A Chronic Disease Score from Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 
197-203. 
CDS-2 is based on Clark DO, et al. "A Chronic Disease Score with Empirically Derived Weights." Medical Care 33, no. 8 (1995): 783-95.
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The predicative validity of six comorbidity adjustment measures was compared 
using administrative claims data from the Department of Defense TRICARE insurance 
program for a group of diabetic patients. These measures included: 1) number of distinct 
medications, 2) index-year total healthcare expenditures, 3) CCI-1, 4) CCI-2, 5) CDS-1, 
and 6) CDS-2. In predicting total healthcare expenditures over one year and two years, 
the sum of index-year healthcare expenditures (model3; model35) was notably better than 
the other five measures. For the prediction of hospitalization over one year and two years, 
the CCI-2 performed the best in the linear regression models (model69; model101), and the 
sum of index-year healthcare expenditures was the best predictor in the logistic 
regression models (model83; model115). In predicting use of emergency department over 
one year and two years, the number of distinct medications performed the best (model130; 
model162). Overall, these measures appeared to be more robust predictors of future 
healthcare expenditures than hospitalizations or emergency department visits. Table 4.1 
summarizes the top two performing comorbidity adjustment measures for the prediction 
of each outcome variable.
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Table 4.1: Top Two Performing Comorbidity Adjustment Measures for the Prediction of Total Healthcare Expenditures, 
Hospitalizations, and Emergency Department Visits 
Best Predictive Power Second Best Predictive Power 
Models Estimates Models Estimates Outcomes 
No. Predictors Adj. R2 (%) c statistic No. Predictors Adj. R2 (%) c statistic 
Healthcare Expenditures 
    1-year total exp. 3 Index-year exp. 35.62 5 CCI-2 11.54 
    2-year total exp. 35 Index-year exp. 31.55 
 
37 CCI-2 12.31 
 
    1-year ≥ 90th percentile 19 Index-year exp. 0.810 18 # of meds 0.767 
    2-year ≥ 90th percentile 51 Index-year exp. 
 




    1-year # of admissions 69 CCI-2 8.05 68 CCI-1 6.87 
    2-year # of admissions 101 CCI-2 9.26 
 
100 CCI-1 8.06 
 
    1-year risk of admissions 83 Index-year exp. 0.684 82 # of meds 0.677 
    2-year risk of admissions 115 Index-year exp. 
 





    1-year # of visits 130 # of meds 9.89 135 CCI-2 6.57 
    2-year # of visits 162 # of meds 12.44 
 
167 CCI-2 8.83 
 
    1-year risk of visits 146 # of meds 0.653 151 CCI-2 0.624 
    2-year risk of visits 178 # of meds 
 
0.654 183 CCI-2 
 
0.626 
Adj. R2: adjusted R2; # : number; exp.: expenditures 
Note: All the models include age and sex as covariates 
CCI-1 is based on Deyo RA, et al. "Adapting a Clinical Comorbidity Index for Use with ICD-9-CM Administrative Databases." Journal of Clinical 
Epidemiology 45, (1992): 613-19. 
CCI-2 is based on Charlson ME, et al. "The Charlson Comorbidity Index Is Adapted to Predict Costs of Chronic Disease in Primary Care Patients." 





4.2 PREDICTION OF TOTAL HEALTHCARE EXPENDITURES 
 
For the prediction of total healthcare expenditures over one year and two years, all 
six measures explained significant proportions of the variation after adjusting for age and 
sex, but the models that included the index-year healthcare expenditures (model3; 
model35) were considerably better than the other measures as they explained 
approximately one-third of the variance in future expenditures. In identifying the 
subgroup of individuals who incurred the highest (≥ 90th percentile) expenditures, the 
index-year healthcare expenditures (model19; model51) also appeared to have the best 
discriminatory power, although the models that included the number of distinct 
medications (model18; model50) exhibited the best calibration. In addition, the measures 
showed improved predictive power when the time horizon was extended from one year to 
two years. In model prediction studies, a c statistic value of less than 0.6 is considered as 
poor, between 0.7 and 0.8 as acceptable, and between 0.8 and 0.9 as excellent.100 Based 
on the results from the logistic regressions, all six measures were acceptable or excellent 
predictors. 
 Contrary to the findings from the current study, two previous studies found the 
count of prescription medications to be a better predictor of healthcare expenditures than 
CCI-1 or CDS-1.101,102 However, the definitions of “distinct” medications are different in 
                                                
100 David W. Hosmer Jr. and Stanley Lemeshow, Applied Logistic Regression, 2nd ed. (New York, NY: 
John Wiley & Sons, 2000). 
101 Schneeweiss et al., "Performance of Comorbidity Scores to Control for Confounding in Epidemiologic 
Studies Using Claims Data." 
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these studies: in the current study, a drug is considered a distinct medication if it has a 
unique chemical structure, whereas in the other studies, two drugs in the same 
pharmacologic or therapeutic class would only be considered as one distinct medication. 
Therefore, direct comparison of the findings should be cautioned. Between the CCI-1 and 
CDS-1, the results from the current study are consistent with an earlier study, which 
found the CCI-1 to be a better predictor of healthcare expenditures than the CDS-1.103 
Only two other studies have compared the predictive power of index-year 
healthcare expenditures with other comorbidity adjustment measures in explaining future 
expenditures. Farley et al. found the CCI-1 and the index-year expenditures to be similar 
in predicting future expenditures, but the count of prescription medications was the most 
powerful predictor.104 In a diabetic Veterans population that was predominantly male, 
index-year expenditures performed similarly as the CCI-1 for the prediction of one-year 
healthcare expenditures, but neither of the measures explained more than four percent of 
the variation.105 In comparison, the current study found the index-year healthcare 
expenditures to be the best predictor of future healthcare expenditures (model3; model35) 
and high-expenditure individuals (model19; model51). One explanation could be that the 
expenses incurred by the TRICARE beneficiaries are almost fully captured by the claims 
                                                
102 Perkins et al., "Common Comorbidity Scores Were Similar in Their Ability to Predict Health Care 
Costs and Mortality." 
103 Onur Baser, Liisa Palmer, and Judith Stephenson, "The Estimation Power of Alternative Comorbidity 
Indices," Value in Health 11, no. 5 (2008). 
104 Farley, Harley, and Devine, "A Comparison of Comorbidity Measurements to Predict Healthcare 
Expenditures." 
105 Maciejewski, Liu, and Fihn, "Performance of Comorbidity, Risk Adjustment, and Functional Status 
Measures in Expenditure Prediction for Patients with Diabetes." 
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records because they only receive medical care through TRICARE or TRICARE-
affiliated programs. However, this hypothesis cannot be tested in the current study. 
 
4.3 PREDICTION OF HOSPITALIZATIONS 
 
For the prediction of the number of hospitalizations, the CCI-2 (model69; 
model101) was the best predictor, but the index-year healthcare expenditures (model83; 
model115) performed the best in predicting the risk of hospitalizations (≥ one hospital 
admission). However, neither predictor showed good model fit. The range of c statistics 
in the current study was similar to those in previous studies: Perkins et al. found that the 
CCI-1, CDS-1, and the count of prescription medications had c statistic values between 
0.636 and 0.670.106 Similarly, Schneeweiss et al. found the range of c statistic values to 
be below 0.7 for the prediction of non-emergency and emergency hospitalizations.107 
Both studies found the number of prescription medications to be a better predictor than 
the CCI-1 or CDS-1, which is consistent with the findings from this study. However, 
since these two other studies did not evaluate the effect of index-year healthcare 
expenditures, the relative performance between the number of distinct medications and 
prior expenditures could not be ascertained. As mentioned earlier, the definition of 
distinct medications in this study is different from those in the two previous studies. 
Overall, the results from the current study confirm previous findings that comorbidity 
                                                
106 Perkins et al., "Common Comorbidity Scores Were Similar in Their Ability to Predict Health Care 
Costs and Mortality." 
107 Schneeweiss et al., "Performance of Comorbidity Scores to Control for Confounding in Epidemiologic 
Studies Using Claims Data." 
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adjustment measures are poor predictors of the risk of hospitalization, as indicated by the 
low c statistic values. 
 
4.4 PREDICTION OF EMERGENCY DEPARTMENT VISITS 
 
In predicting the number and risk (≥ one visit) of emergency department visits, 
the number of distinct medications was the most powerful predictor (model130; model146; 
model162; model178). Augmenting the number of distinct medications with the other 
measures in the prediction models showed improved predictive power. Among the six 
measures, only the index-year expenditures models showed poor model fit (model147; 
model179). Overall, all the measures examined in the current study were poor predictors of 
risk of emergency department use. One explanation for why a simple count of distinct 
medications was a better predictor than either CDS-1 or CDS-2 in the study is that 
misclassification may have occurred. That is, a drug that is used for multiple indications 
may have been grouped to a different diagnosis incorrectly when matching medications 
to the listed diagnoses in the CDS. Little has been done to examine the utility of 
comorbidity adjustment measures in predicting emergency department visits. In one 
previous study, the CCI-1 was found to be not associated with non-urgent emergency 
department use among a group of type II diabetic patients.108 
                                                
108 Shang-Jyn Chiou et al., "Use of the Emergency Department for Less-Urgent Care among Type 2 
Diabeticss under a Disease Management Program," BMC Health Services Research 9 (2009). 
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4.5 COMPARISON OF MEDICATION-BASED WITH DIAGNOSIS-BASED MEASURES 
 
The results from this study imply that either diagnosis-based or medication-based 
comorbidity adjustment measures may be preferable depending on the outcome variable 
of interest. Based on the proportion of variation explained, the CCI-1 and CCI-2 seemed 
to be most predictive of total healthcare expenditures, followed by hospitalizations, and 
then emergency department visits. On the other hand, the CDS-1 and CDS-2 were most 
predictive of emergency department visits, followed by total healthcare expenditures and 
hospitalizations. However, while the CCI-1 and CCI-2 appeared to be better than the 
CDS-1 and CDS-2 in predicting the number of hospitalizations and total healthcare 
expenditures, a simple count of distinct medications was a better predictor of the number 
of emergency department visits than diagnosis-based measures. 
 Two competing hypotheses exist with regards to the relative performance of 
diagnosis-based and medication-based comorbidity adjustment measures.109 One 
hypothesis is that diagnosis-based measures are superior to medication-based measures 
because diagnosis-based measures account for diagnoses untreated by drugs, and two 
conditions treated by the same drug (e.g., cancer and rheumatoid arthritis treated by 
methotrexate) would also be captured in the indices. The alternative hypothesis is that 
medication-based measures are superior because patients may only have their most 
relevant diagnoses coded in administrative claims data, and prescriptions filled by 
                                                
109 Schneeweiss et al., "Performance of Comorbidity Scores to Control for Confounding in Epidemiologic 
Studies Using Claims Data." 
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patients may be a better reflection of their true health status. However, the results from 
the current study support neither hypothesis. 
 It has been suggested that medication-based measures could be used in 
conjunction with diagnosis-based measures in the same prediction model to increase the 
model’s explanatory power, as these two types of comorbidity adjustment measures may 
account for variation that is otherwise not measured. Results from the regression models 
in this study showed that combination models did exhibit better predictive power, but the 
improvements were limited. Furthermore, there appears to be a “ceiling effect” that could 
be achieved by incorporating several comorbidity adjustment measures in one single 
model: the CDS-1 and CDS-2 seemed to have limited effect on the predictive power of 
combination models that already include the number of distinct medications, total 
healthcare expenditures, and the CCI. 
Even if the combination models result in increases in predictive power that are 
statistically significant, such improvements may have little practical significance. For the 
prediction of emergency department visits, the combination models examined in this 
study remained poor predictors as the c statistic values were below 0.7. Using more than 
one comorbidity adjustment measure in one study may not be ideal because it requires 
additional time and resources for coding and data analysis. In general, diagnosis-based 
measures are easier to use because medication-based measures such as the CDS require 
continued updates of new medications that are used to treat the specified chronic 
conditions. However, it should be noted that a simple count measure such as the number 
of distinct medication and a prior utilization measure such as the index-year total 
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healthcare expenditures were as good or better than the CCI or CDS in this study, and 
using these two alternative measures may be more efficient. 
 
4.6 COMPARISON OF THE ORIGINAL AND THE UPDATED CHARLSON COMORBIDITY 
INDICES 
 
At the time of this study, no other studies were found to have validated the utility 
of the updated Charlson Comorbidity Index (CCI-2) after it was developed. In the current 
study, the CCI-2 performed consistently better than the CCI-1 in predicting all outcome 
variables for diabetic patients. The improved performance is likely a result of the 
inclusion of additional diagnoses and medication use (depression, hypertension, skin 
ulcers, and the use of warfarin) that are not covered in the CCI-1. Previous studies have 
shown that depression is associated with increased healthcare costs in diabetic 
patients.110,111 However, whether one or more of these additional risk factors contribute to 
the increased predictive power warrants further investigation. Among the four new risk 
factors in CCI-2, it may be of particular interest to examine whether eliminating the use 
of warfarin from the CCI-2 would significantly impact its predictive power. As pharmacy 
claims data may sometimes be unavailable to researchers, a “modified” CCI-2 that 
requires no prescription claims data may be useful in epidemiologic research. Overall, the 
findings from the current study suggest that, in a diabetic population under the age of 65, 
                                                
110 Gregory E. Simon et al., "Diabetes Complications and Depression as Predictors of Health Service 
Costs," General Hospital Psychiatry 27 (2005). 
111 Egede, Zheng, and Simpson, "Comorbid Depression Is Associated with Increased Health Care Use and 
Expenditures in Individuals with Diabetes." 
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the CCI-2 should be considered in place of the CCI-1 when the outcomes of interest are 
total healthcare expenditures, hospitalizations, and emergency department visits. 
 
4.7 UTILITY OF COMORBIDITY ADJUSTMENT MEASURES 
 
The six comorbidity adjustment measures examined in the current study showed 
varying degrees of predictive power, and the proportion of variation explained by these 
measures generally fell below 10 percent. The results suggest that these measures may be 
a useful tool to control for confounding in administrative database research, but the 
effects are limited. There are several reasons why comorbidity adjustment measures only 
have limited explanatory power in predicting health services utilization: 
First, administrative claims databases are designed for billing purposes but not for 
use with comorbidity adjustment measures. That is, such databases may reflect the 
intensity of resource utilization more accurately than they reflect a patient’s health status. 
As an example, for medication-based measures such as the CDS, if the physician does not 
prescribe medications for a medical condition or if the patient does not fill the prescribed 
medication, then the CDS will not be able to detect the medical condition. For diagnosis-
based measures such as the CCI, a patient’s comorbid conditions may not be fully 
captured because the conditions may not be relevant to the principal diagnosis when the 
patient receives medical care and thus not recorded in the claims. In other words, the 
predictive power of comorbidity adjustment measures is limited by the available data. 
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Second, both versions of the CCI and the CDS were originally developed from 
patient cohorts of different disease states to predict several different outcomes, and 
previous literature indicates that the performance of comorbidity adjustment measures 
varies when different patient populations or outcomes are examined. The CCI-1 was 
derived from a cohort of breast cancer patients to predict one-year mortality, and the 
CCI-2 was developed from a group of primary care patients to predict annual healthcare 
costs. Thus, the calibrations of weights in these two indices were a function of the 
outcomes under investigation and the distribution of chronic diseases in the patient 
populations. This is also true for the CDS-1 and CDS-2. It is likely that a chronic 
condition that is highly predictive of mortality may not predict healthcare expenditures 
well, and vice versa. The findings from the current study support the hypothesis that 
comorbidity adjustment measures could be more predictive of one health outcome over 
another. 
Third, the measures examined in this study were designed for use in general 
populations, and chronic conditions that are more relevant to diabetic patients may have 
been omitted in these indices. Young et al. developed a Diabetes Complications Severity 
Index (DCSI) that uses both diagnosis codes and laboratory data to identify seven 
diabetes-related complications, including retinopathy, nephropathy, neuropathy, 
cerebrovascular complications, cardiovascular complications, peripheral vascular disease, 
and metabolic complications.112 The DCSI was shown to be a slightly better predictor of 
                                                
112 Bessie Ann Young et al., "Diabetes Complications Severity Index and Risk of Mortality, 
Hospitalizations, and Healthcare Utilization," The American Journal of Managed Care 14, no. 1 (2008). 
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mortality and hospitalization than a simple count of medications.113 However, when 
compared with the CCI and other comorbidity adjustment measures, the DCSI had very 
poor predictive power in predicting healthcare expenditures.114 The reason could be that 
the DCSI only accounts for a limited range of diabetes-related complications but not 
other comorbidities that may be highly associated with healthcare expenditures.  
The performance of prediction models is often evaluated using the area under the 
receiver-operator curve, or the c statistic, which indicates a model’s discriminatory 
power. However, one should interpret the c statistic cautiously because it is only a 
function of how well a model can rank order cases versus non-cases, but it does not 
reflect the magnitudes of the differences in rank. For example, the c statistic does not 
differentiate between individuals who have CCI scores of two and five if they are both 
compared to individuals who have a CCI score of zero: in this case, perfect 
discrimination is achieved because individuals with scores of two and five are treated as 
cases, and individuals with a score of zero are treated as non-cases. However, in the 
clinical setting, a patient with a CCI score of five may be significantly sicker than a 
patient with a CCI score of two and thus warrant additional medical attention or different 
treatment recommendations. Therefore, a model’s calibration should also be taken into 
consideration when evaluating model performance as it indicates how well the predicted 
distribution of cases matches the observed distribution.  
                                                
113 Ibid. 
114 Maciejewski, Liu, and Fihn, "Performance of Comorbidity, Risk Adjustment, and Functional Status 
Measures in Expenditure Prediction for Patients with Diabetes." 
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In this study, model calibration was tested using the Hosmer-Lemeshow 
goodness-of-fit chi-square test, where a statistically significant chi-square value indicates 
lack of model fit and poor calibration. For the prediction of one-year risk of 
hospitalization, the number of distinct medications and index-year healthcare 
expenditures showed similar discriminatory power based on the c statistics, but the model 
that included the number of distinct medications had better model fit. In this case, the 
number of distinct medications may be a more ideal adjuster for comorbidity than the 
index-year expenditures. To date, model calibration receives relatively little attention in 
risk model comparison studies, but the utility of comorbidity adjustment measures should 
be assessed based on both the discrimination and calibration of the prediction model. 
4.8 LIMITATIONS OF THE STUDY 
 
The results from this study should be interpreted in light of the following 
limitations: 
First, the study results may have been biased toward patients who had been 
hospitalized. In the TRICARE claims database, a total of up to 20 ICD-9-CM fields may 
be recorded in the inpatient setting, while only a maximum of eight ICD-9-CM fields 
may be recorded for an outpatient visit. Therefore, it is likely that patients who were 
hospitalized incidentally had more diagnoses captured in the database. As such, these 
patients may have accounted for individuals who produced higher comorbidity scores. 
However, the distributions of scores derived from the comorbidity adjustment measures 
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in this study appeared similar to those in previous literature, with the majority of the 
patients at the lower end of the spectrum and a few patients with outlying high values.  
Second, the study findings may not be generalizable to other patient populations. 
The Department of Defense TRICARE population may not be representative of patient 
populations who receive care through other insurers. The study population is limited to 
people under the age of 65 who had type I or II diabetes and received care for their 
diabetes. 
Third, expenses incurred outside the TRICARE system were not captured by the 
claims data. As such, the predictor and outcome that included the sum of healthcare 
expenditures may have been underestimated. However, results from the current study 
indicated that the index-year expenditures appeared to be a robust predictor of healthcare 
utilization and expenditures. 
 Fourth, coding practices may be different across hospitals and clinics within the 
TRICARE system, resulting in inconsistencies in data quality. The claims data may also 
be incomplete, as only the most relevant and current diagnoses may be recorded at an 
ambulatory visit or hospital admission. Inaccuracy of administrative coding systems may 
be a concern, including both false-positive and false-negative records of diagnoses and 
prescription fills. However, automated databases have been shown to be an efficient way 
to identify comorbidities and complications of diabetes for epidemiologic and health 
services research.115 
                                                
115 Katherine M. Newton et al., "The Use of Automated Data to Identify Complications and Comorbidities 
of Diabetes: A Validation Study," Journal of Clinical Epidemiology 52, no. 3 (1999). 
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Fifth, certain demographic and clinical variables were not available for this study, 
such as race, ethnicity, duration of diabetes, and body mass index. These risk factors may 
be important predictors of healthcare utilization and expenditures for diabetic patients. 
4.9 CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH 
 
Comorbidity adjustment measures are used for different purposes in 
epidemiological research. They can be used to correct for confounding or predict study 
outcomes. As such, the purpose of their use may dictate when and whether a particular 
measure should be used. Although the CCI and CDS seemed to have limited power to 
predict hospitalizations and emergency department visits, researchers may still consider 
using these measures to adjust for comorbidity to accurately measure the associations 
between the independent and dependent variables. Nevertheless, prior utilization such as 
the index-year healthcare expenditures could be a more powerful predictor of future 
healthcare expenditures, and simple count measures such as the number of distinct 
medications could be a more efficient way to adjust for comorbidity. The CCI-2 also 
appeared to have better predictive power than the CCI-1 for use in a diabetic population. 
Suggestions for future research include: 
1) developing diabetes-specific comorbidity adjustment measures to 
improve comorbidity adjustment for diabetic patients; 
2) improving existing comorbidity adjustment measures by recalibrating 
scoring algorithms for use in different disease states; 
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3) validating the updated Charlson Comorbidity Index for use in different 
patient populations and for different health outcomes; and 
4) assessing the performance of diagnosis-based and medication-based 
measures with prior utilization and simple count measures such as the 




Appendix A. Charlson Comorbidity Index – Weights, Diagnoses and the 
Deyo, Dartmouth-Manitoba, and D’Hoore ICD-9 Codes 
 
Weight Diagnoses* Deyo codes† Dartmouth-Manitoba codes‡  D’Hoore codes
§  
1 Myocardial infarction 




428.x 402.01, 402.11, 
402.91, 425.x, 
428.x, 429.3 























430-437.x, 438 362.34, 430-436, 
437-437.1, 437.9, 





























Weight Diagnoses Deyo codes Dartmouth-Manitoba codes D’Hoore codes 






1 Diabetes 250.0x-250.3x, 250.7x 
250.0x-250.3x N/A 
1 Connective tissue disease 
N/A N/A 710, 714, 725 



















250.4x-250.6x 250.4x-250.9x 250 
2 Any tumor 140-195 




















070, 570, 572 
6 Metastatic cancer 
196.x-199.x 196.x-199.x 196-199 
6 AIDS 042.x-044.x N/A N/A 
ICD-9: The International Classification of Diseases, 9th Revision; N/A: Not Applicable; AIDS: Acquired 
Immunodeficiency Syndrome 
(P) indicates ICD-9 procedure codes 
* Charlson, Mary E., Peter Pompei, Kathy L. Ales, and C. Ronald MacKenzie. "A New Method of 
Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation." Journal of 
Chronic Diseases 40, no. 5 (1987): 373-83. 
† Deyo, Richard A., Daniel C. Cherkin, and Marcia A. Ciol. "Adapting a Clinical Comorbidity Index for 
Use with ICD-9-CM Administrative Databases." Journal of Clinical Epidemiology 45, (1992): 613-19. 
‡  Romano, Patrick S., Leslie L. Roos, and James G. Jollis. "Further Evidence Concerning the Use of a 
Clinical Comorbidity Index with ICD-9-CM Administrative Data." Journal of Clinical Epidemiology 46, 
no. 10 (1993): 1085-90. 
§ D'Hoore, William, André Bouckaert, and Charles Tilquin. "Practical Considerations on the Use of the 
Charlson Comorbidity Index with Administrative Data Bases." Journal of Clinical Epidemiology 49, no. 
12 (1996): 1429-33. 
 
141 
Appendix B. Updated Charlson Comorbidity Index – Additional 
Conditions, Weights, ICD-9 Codes, and GCN Codes 
 
Weight Diagnoses ICD-9 codes GCN codes 
1 Depression 296.2x-296.3x, 311.x N/A 
1 Use of warfarin N/A 25790-25798 
1 Hypertension 401.x N/A 
2 Skin ulcers/cellulitis 682.x, 707.x N/A 
ICD-9: The International Classification of Diseases, 9th Revision; GCN: Generic Code Number; N/A: Not 
Applicable 
* These diagnoses are included in Charlson et al.’s 2008 adaptation: "The Charlson Comorbidity Index Is 
Adapted to Predict Costs of Chronic Disease in Primary Care Patients." Journal of Clinical Epidemiology 





Appendix C. Chronic Disease Score – Conditions, Medication Classes, 
and Weights 
 
Conditions Medication class or classes Weight 
Heart disease (1) Anti-coagulants, hemostatics 
(2) Cardiac agents, ACE inhibitors 
(3) Diuretic loop 
One class = 3 
Two classes = 4 
Three classes = 5 
Respiratory illness (1) Isoproterenol 
(2) Beta-adrenergic, miscellaneous 
(3) Xanthine products 
(4) Respiratory products including 
bronchodilators and mucolytics 
but excluding cromolyn 
(5) Epinephrine 
One class = 2 
Two or more classes = 3 
Asthma, rheumatism Glucocorticoids Score = 3 






Score = 3 






Dopamine receptor agonists 
Score = 3 
Hypertension (1) Antihypertensives (except ACE 
inhibitors) or calcium channel 
blockers 
(2) Beta blockers, diuretics 
If class (1) = 2 
If class (2) and not (1) = 1 
Diabetes Insulin, oral hypoglycemics Score = 2 
Epilepsy Anticonvulsants Score = 2 
Asthma, rhinitis Cromolyn 
Leukotriene modifiers 
Score = 2 
Acne (1) Antiacne tretinoin 
(2) Topical macrolides 
Either class with two or 
more prescriptions filled = 
1 
Ulcers Cimetidine Score = 1 
Glaucoma Ophthalmic miotics Score = 1 
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Conditions Medication class or classes Weight 
Gout, hyperuricemia Uric acid agents Score = 1 
High cholesterol Antilipemics Score = 1 
Migraines Ergot derivatives Score = 1 
Tuberculosis Antitubercular agents Score = 1 
ACE: Angiotensin Converting Enzyme 
L-Dopa: 3,4-dihydroxy-L-phenylalanine 
DMARDs: Disease-modifying antirheumatic drugs 
Anti-TNFs: Anti-tumor necrosis factors 
COMT inhibitors: Catechol-O-methyl transferase inhibitors 
Medications in italics are drugs that became available after the Chronic Disease Score was developed 1992. 
These drugs were included in the study for the calculation of the Chronic Disease Score. 
* Von Korff, Michael, Edward H. Wagner, and Kathleen Saunders. "A Chronic Disease Score from 
Automated Pharmacy Data." Journal of Clinical Epidemiology 45, no. 2 (1992): 197-203 
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Appendix D. Chronic Disease Score – Explanatory Variables, 
Medication Classes, and Weights for Prediction of Total Cost, 
Outpatient Cost, and Primary Care Visits 
Weights 








Intercept  2011.4 539.0 1.44 
Age (year)  
  18-24  -1684.8 -283.7 -0.41 
  25-34  -1592.7 -215.8 -0.24 
  35-44  -1704.8 -239.3 -0.29 
  45-54  -1616.4 -208.8 -0.24 
  55-64  -1418.2 -147.5 -0.20 
  65-74  -967.0 -24.9 -0.06 
  75-84  -505.3 27.2 0.18 
  85+  0.0 0.0 0.00 












Epilepsy Anticonvulsant barbiturates & 
congeners, 




771.5 402.2 0.29 




























Miscellaneous vasolidating agents 
Tuberculosis Antitubercular antibiotics, 
Miscellaneous antimycobacterials 






















4853.2 2368.7 3.53 
High cholesterol Antilipemics, 
Cholesterol absorption inhibitors, 
Fibric acid derivatives, 
Miscellaneous antilipemic agents 
293.4 302.1 0.32 
Malignancies Antineoplastics, 
Colony-stimulating factors, 
Miscellaneous antinausea agents, 
Ondansetron 








Dopamine receptor agonists 

















Heart disease Beta-adrenergic blockers, 







Class 1A, 1C, 1I antiarrhythmics 










1108.4 423.9 0.91 
Glaucoma Diuretic carbon-anhydrase 
inhibitors, 




351.7 330.7 0.18 
Cystic fibrosis Mucolytics, 
Pancreatic enzymes 
2341.6 365.6 0.10 
Renal failure Potassium removing resins, 
Kayexalate 
16579.0 1675.1 -0.46 
Liver failure Ammonia detoxicants 1519.1 798.5 0.33 
Ulcers Histamine H2 blockers, 
Prostaglandin, 
Misoprostil, 
Proton pump inhibitors, 
Omeprazole, 
Protectants 
797.1 351.1 0.54 
Transplants Cyclosporine-A, 
Azathioprine 
3411.6 2733.5 -0.99 
Respiratory 
illness, asthma 
Beta agonist bronchodilators, 
Xanthines, 

















Thyroid replacement antithyroid 
agents 
282.8 135.5 0.23 
Gout Colchicine, 
Uric acid inhibitors 












137.6 145.7 0.48 
Depression Tricyclic antidepressants, 
Monoamine oxidase inhibitors, 
Selective serotonin reuptake 
inhibitors, 





545.4 385.9 0.67 





1438.7 466.7 0.50 
Mania Lithium 260.1 416.9 0.32 
Anxiety, tension Benzodiazepines, 
Meprobamate, 
Miscellaneous antianxiety agents 
480.0 292.1 0.52 
Pain Narcotics 
Opiate partial agonists 
633.2 261.8 0.46 
ACE: Angiotensin Converting Enzyme 
L-Dopa: 3,4-dihydroxy-L-phenylalanine 
COMT inhibitors: Catechol-O-methyl transferase inhibitors 
DMARDs: Disease-modifying antirheumatic drugs 
Anti-TNFs: Anti-tumor necrosis factors 
Medications in italics are drugs that became available after the Chronic Disease Score was developed 1995. 
These drugs were included in the study for the calculation of the Chronic Disease Score. 
* Clark, Daniel O., Michael von Korff, Kathleen Saunders, Willaim M. Baluch, and Gregory E. Simon. "A 
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